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ABSTRACT 
Pregnancy-associated breast cancer (PABC) is commonly defined as a breast cancer (BC) 
diagnosed during pregnancy or within one or two years after delivery. The risk of BC is lower 
than expected during pregnancy with a small rebound within 2 years after delivery, compared 
to non-pregnant women of the same age. Although a rare event, there is evidence that women 
with PABC have a poorer prognosis compared to women with BC diagnosed not near a 
pregnancy (non-PABC). It is important to improve the understanding of underlying 
mechanisms and identify factors that may influence outcome, including the role of detection 
and tumour biology. The possible influence of pregnancy exposures on detection and tumour 
biology may be time-varying, with different effects during the pregnancy period compared to 
time windows further away from delivery. Since a transient risk has been reported 5-10 years 
post-delivery, it is also of interest to compare pregnancy-associated tumours to tumours 
diagnosed further away, say up to ten years, from delivery with respect to tumour biology and 
prognosis. 
Having a relative with breast cancer is an established risk factor for breast cancer, in 
particular at a young age. Women with a family history of breast cancer may be more likely 
to have pre-malignant breast cells at a young age, and could be more susceptible to 
pregnancy-related exposures, such as elevated levels of endogenous hormones. Study III 
assessed the risk pattern for breast cancer during pregnancy and up to ten years after delivery 
in relation to family history of breast cancer using a cohort of 3.5 million women aged 15-44 
years identified in the Swedish Multi-Generation Register and the Swedish Cancer Register. 
In total, 15,548 women had a recorded BC diagnosis of which 1,208 were PABC. To reduce 
the comparison population and improve computational efficiency, a case-cohort design was 
utilised. The results showed that a family history of BC did not affect the risk pattern around 
pregnancy and up to 10 years post-delivery, indicating that pregnancy-related exposures do 
not interact with the familial pre-disposition for BC in these women. 
Results from several studies have suggested that BC tumours diagnosed around delivery have 
adverse tumour characteristics, such as advanced TNM stage and triple-negative subtype, but 
it remains unclear if adverse tumour characteristics can fully explain the worse prognosis in 
women with PABC. Studies II and IV assessed TNM stage in cohorts of patients diagnosed 
with BC during pregnancy and up to ten years post-delivery using information from the 
Swedish Cancer Register for years 2002-2009 (study II) and the Swedish Breast Cancer 
Quality Register for years 1992-2009 (study IV). Study IV also assessed histological grade 
and tumour biology, such as hormone receptor status. The results showed that tumours 
detected during pregnancy and within one year of delivery were more often advanced, of high 
grade and hormone receptor negative (triple-negative and non-luminal Her2 positive 
subtypes) compared to nulliparous women. These associations were most pronounced in 
tumours diagnosed during the first six months post-delivery. In combination with the 
previously observed lower risk during pregnancy, these findings could reflect diagnostic 
delays, resulting in more advanced tumours at diagnosis, or a suppression of hormone 
responsive tumours around delivery. 
With the aim to investigate prognosis in women with PABC, two partly over-lapping cohorts 
of BC patients were identified in the Swedish Cancer Register for years 1963-2002 (study I) 
and in the Breast Cancer Quality Register for years 1992-2009 (study IV), including 1,110 
and 778 women with PABC, respectively. The association between PABC and mortality was 
analysed using Cox regression and flexible parametric models. The results from study I and 
IV corroborated previous findings that women with PABC have a poorer prognosis compared 
to women with non-PABC. The mortality was highest in women diagnosed 0-6 months after 
delivery, and remained elevated up to eight years after diagnosis, in comparison to women 
diagnosed not near a delivery. However, following adjustment for tumour characteristics, the 
difference in mortality between women with PABC and women with non-PABC was 
attenuated and non-significant (study IV). These findings suggest that although PABC is 
associated with more advanced and aggressive tumours, the outcome is similar to that in 
women with non-PABC when taking tumour characteristics into account.  
For comparison, we also assessed tumour characteristics and prognosis in women diagnosed 
with BC 2-10 years after delivery (study IV). A transient risk of BC around 5-10 years after 
delivery has been reported previously. Compared to nulliparous women, women diagnosed 2-
5 years post-delivery did not differ in tumour size, grade and ER status, but more often 
presented with spread to lymph nodes, negative PR status and non-luminal Her2 positive 
subtype. Women with BC diagnosed 2-5 years post-delivery also exhibited a poorer 
prognosis compared to nulliparous women, which remained significant after adjustment for 
T/N stage and hormone receptor status. These findings could indicate different mechanisms 
for risk, detection and prognosis in women diagnosed 2-5 years after delivery compared to 
women with PABC. 
In conclusion, the findings indicate that pregnant and lactating women exhibit different 
patterns of BC risk, tumour biology and prognosis compared to other pre-menopausal women 
with BC. The poorer prognosis observed in women with PABC can largely be explained by 
adverse tumour characteristics at diagnosis. The effects of pregnancy appear to persist beyond 
2 years after delivery.  
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1 BACKGROUND 
Breast cancer (BC) during pregnancy or shortly after delivery has difficult implications for 
the patient and her family. Since women are postponing childbearing into ages where breast 
cancer is more common, the incidence of breast cancer coinciding with pregnancy is expected 
to increase in the future. Because of the observed poorer prognosis of pregnancy-associated 
breast cancer (PABC), i.e. BC diagnosed during pregnancy or within one or two years of 
delivery, it is of interest to quantify the breast cancer risk pattern around delivery, to 
characterise the tumours in different time-windows around delivery and to assess the survival 
in this young patient group. The possible influence of pregnancy exposures on detection and 
tumour biology may be different during the pregnancy period and further away from delivery. 
Some studies have found evidence of adverse prognostic factors in breast tumours diagnosed 
near pregnancy, such as advanced stage and hormone receptor negativity, and a subsequently 
poor survival. However, it remains unclear if adverse tumour characteristics can fully explain 
the poorer prognosis.  
Less than 10% of all breast cancer tumours in Sweden are detected in women below 45 years, 
and only 7% of those are diagnosed during pregnancy and up to two years post-delivery [1]. 
Consequently, many studies on pregnancy and breast cancer lack power to provide firm 
answers. Studies of pre-menopausal breast cancer require long follow-up, large populations at 
risk or multicentre collaborations to accrue a sufficient number of cases. Utilising information 
available in Swedish population-based registers, this thesis aimed to shed light on some of the 
outstanding questions in this field.  
1.1 BREAST CANCER IN PRE-MENOPAUSAL WOMEN 
1.1.1 Incidence and survival by age and period 
In 2013, 7,816 women in Sweden were diagnosed with breast cancer [2, 3]. Among 7,223 
women who had breast cancer as their first recorded tumour in life, 626 (8.7%) were below 
45 years at the time of diagnosis and only 115 (1.6%) below 35 years of age [2]. The 
incidence of pre-menopausal breast cancer has increased in Sweden over the last decades 
(Figure 1.1). The survival after breast cancer has also increased over calendar time; the 5-year 
relative survival is now over 90% in Swedish women below 50 years at diagnosis (Figure 
1.1). 
1.1.2 Risk (and prognostic) factors for pre-menopausal breast cancer 
Age 
Increasing age represents the strongest risk factor for breast cancer, with a strong age gradient 
also in women below 45 years [4, 5] (Figure 1.1). Breast tumours in young women often have 
more untoward biological characteristics [5-8] and have a poorer prognosis, compared to 
post-menopausal breast cancer [9-12]. 
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Figure 1.1 Trends of breast cancer incidence and survival in Sweden [2]. Note: Y-axis for incidence 
on log scale.  
 
 
Family history of BC 
Family history of breast cancer is defined as having a biological relative with breast cancer. 
A family history of breast cancer confers a nearly doubled risk of breast cancer at any age, 
with even stronger effects observed in younger women [13, 14]. If the relative is a first degree 
relative (mother, sister or daughter) or had BC herself at a young age, then the risk is higher.  
Family history of BC is a proxy for both genetic risk and shared environmental risk. Only 
around 24% of the familial risk of BC can be attributed to known risk-increasing mutations 
such as BRCA1 and BRCA2 [15]. There is evidence that family history of breast cancer is 
associated with an increased awareness of BC, more frequent radiologic examinations and 
early detection of BC [16], but not a worse prognosis [17, 18]. 
Reproductive factors 
Low age at menarche is associated with an increased risk of pre-menopausal BC [19]. 
Compared to parous women, nulliparous women have a lower risk of pre-menopausal breast 
cancer before age 40, but are at an increased risk after age 40, compared to parous women 
[5]. Age at first birth does not affect the breast cancer risk until after age 40, where first 
birth before age 25 is associated with a lower risk [5]. 
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Endogenous hormones 
Throughout life, endogenous hormones play an important role for the risk of developing 
breast cancer [20]. However, data are limited regarding the role of endogenous hormones 
(e.g. estrogen, progesterone) and the risk of breast cancer in pre-menopausal women (mainly 
due to difficulties in measuring these hormonal levels in women with menstrual cycles). 
Based on data from the Nurses’ Health Study (a large US cohort study investigating women’s 
health) Eliassen et al [21] observed that women with high concentrations of free estradiol 
during the follicular phase of the menstrual cycle were at a higher risk for pre-menopausal 
BC. The same study also found that the association between free and total estradiol was 
stronger for the risk of developing ER/PR positive tumours [21]. 
The epidemiological evidence on progesterone levels and overall risk of pre-menopausal BC 
is inconclusive [21, 22], while no association has been found between prolactin levels and 
risk of pre-menopausal BC [23]. 
Circulating levels of estrogen and progesterone have been reported to be higher in women 
with benign breast disease, which is a risk factor for breast cancer, although less so in pre-
menopausal women [24]. 
Other factors 
A high educational level is not only associated with a higher risk of BC, but also with a 
better survival among pre-menopausal women [25, 26].  
Current use of oral contraceptives is associated with an increased risk for pre-menopausal 
breast cancer, especially prior to first childbirth [5, 27, 28].  
A history of breastfeeding is an established protective factor for post-menopausal breast 
cancer, but it remains unknown if current or recent breastfeeding is protective against breast 
cancer development in pre-menopausal women [29].  
Obesity is associated with a reduced risk of breast cancer in pre-menopausal women [5, 30]. 
Alcohol intake is an established BC risk factor, but the association appears to be less 
pronounced in pre-menopausal women [31-33]. Smoking is not a risk factor for pre-
menopausal breast cancer [32, 34].  
1.1.3 Tumour characteristics and BC subtypes 
Breast cancer tumours are described and classified according to histology, TNM stage, grade 
and molecular biomarkers.  
Histology 
Breast cancer origins from different cell types in the epithelial (carcinoma) or fibrous 
(sarcoma) tissue of the breast, where the first predominate. Histopathologic subtypes of breast 
 4 
carcinomas include: ductal, lobular, mucinous, tubular, medullary, papillary and other rarer 
subtypes [35, 36]. Invasive breast carcinoma (unlike cancer in situ) has spread beyond the 
basal membrane of the epithelium. 
TNM stage 
The TNM system is used to classify the extent of tumour spread at diagnosis, where T 
represents tumour size, N spread to nearby (regional) lymph nodes, and M the presence of 
distant metastasis [37] (Table 1.1). By combining the T, N and M stage, breast cancer 
tumours are classified into TNM stage 0 (cancer in situ), TNM stage I (small primary 
tumour, no spread), TNM stage II (small tumour, limited nodal engagement, or medium-
large tumour, no nodal engagement), TNM stage III (massive nodal engagement regardless 
of tumour size, or large tumour, limited nodal engagement) or TNM stage IV (distant 
metastasis). TNM stage can be assessed prior to surgery (clinical TNM) or post-surgery 
(pathologic TNM), where pathologic TNM is more precise.  
Tumours diagnosed in pre-menopausal women have on average a more advanced TNM stage 
at presentation compared to post-menopausal breast cancer [11]. TNM stage has been 
suggested to explain the poorer prognosis in pre-menopausal women compared to post-
menopausal women, except in the youngest age group <35 years [11]. 
Table 1.1 TNM classification of breast cancer [37]. 
TNM Stage T N M Prognosis 
0 Tis N0 M0 Best survival 
I T1 N0 M0  
II T0-T2 N1 M0  
 T2-T3 N0 M0  
III T0-T2 N2 M0  
 T3 N1-N2 M0  
 T4 N0-N2 M0  
 Any T N3 M0  
IV Any T Any N M1 Poorest survival 
T stage: Tis: tumour in situ, T1: 0-20mm; T2: 21-50mm; T3: >50 mm; T4: Chest wall/skin ulceration, 
skin nodules, inflammatory. 
N stage: N0: no spread to lymph nodes; N1: 1-3 axillary lymph nodes affected or internal mammary 
lymph nodes somewhat affected; N2: 4-9 lymph nodes affected or internal mammary lymph nodes 
affected; N3: 10+ lymph nodes affected or internal mammary lymph nodes affected or spread to 
supraclavicular lymph nodes. 
M stage: M0: absence of distant metastasis; M1: presence of distant metastasis 
 
Grade 
Elston grade is a measure of the histologic grade, i.e. the differentiation or maturation of the 
tumour cells. A tumour of grade III is more aggressive (poorly differentiated) than a tumour 
of grade I (well differentiated) [38].  
Pre-menopausal breast cancer is more often of grade III compared to post-menopausal breast 
cancer, and the prognosis is poorer for grade III compared to grade I tumours [7, 11, 39]. 
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Molecular biomarkers 
Molecular markers on the surface or inside the tumour cells have become increasingly 
important in the classification of cancer. The most important markers for breast cancer 
include the estrogen receptor (ER), the progesterone receptor (PR) and the human 
epidermal growth factor receptor 2 (Her2).  
Pre-menopausal breast cancer tumours are more often ER/PR negative [7, 11, 39], while no 
difference has been observed for Her2 [39]. A Swedish study [11] reported that 42% of 
tumours diagnosed in women <35 years were hormone receptor negative compared to 27% in 
women 35-39 years. 
Ki-67 assesses the proliferation (speed of cell division) of the tumour cells. Pre-menopausal 
BC tumours are more often highly proliferating which is associated with a worse prognosis 
[39]. 
According to these biomarkers, breast cancer is further classified into subtypes with distinct 
disease characteristics, treatment recommendations and prognosis [40-44]. The subtypes 
include (Table 1.2):  
 Luminal A: ER positive, PR positive, Her2 negative, Ki67 low 
 Luminal B: ER positive, PR any, Her2 positive (or Her2 negative with Ki67 high) 
 Her2 positive (non-luminal): ER/PR negative, Her2 positive, Ki67 any 
 Triple-negative (basal-like): ER/PR negative, Her2 negative, Ki67 any 
In an American study [45], the distribution of these subtypes in young women (<40 years) 
was estimated to: Luminal A (33%), Luminal B (35%), Her2 positive (11%) and triple-
negative (21%), which is different from post-menopausal breast cancer where the vast 
majority of tumours were Luminal A type tumours (60-70%). The Luminal B subtype was 
also more common in pre-menopausal compared to post-menopausal women [45]. Pre-
menopausal women exhibit a poorer prognosis, compared to post-menopausal women, also 
within these subtypes [44]. 
Table 1.2 Overview of BC subtypes by ER, PR, Her2 and Ki67 status [43] and their prognosis [44]. 
Subtype ER PR Her2 Ki67 Prognosis 
Luminal A pos pos neg low Best survival 
Luminal B (Her2-) pos neg/low neg high  
Luminal B (Her2+) pos any pos any  
Her2-positive neg neg pos any  
Triple-negative neg neg neg any Poorest survival 
pos=positive, neg=negative 
 
1.1.4 Diagnosis, screening and treatment 
The most common symptom of breast cancer in young women is a lump, while pain and 
secretion are less common [46]. The vast majority of pre-menopausal breast cancers are 
diagnosed in symptomatic women. Organised, invitational mammography screening was 
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introduced in Sweden in the late 1980’s from 40 or 50 years of age. Since the 1990’s women 
aged 40 to 49 years have been invited to screening in about half of Sweden’s counties [47]. 
Mammography is less sensitive in pregnant women, and although the recommendation of the 
National Board of Health and Welfare (Socialstyrelsen, NBHW) is to invite pregnant or 
lactating women to the screening programme [48], the participation rates are likely to be low 
in this group.  
The diagnostic procedure includes a triple test of 1) clinical examination, 2) mammogram or 
ultrasound and 3) fine needle or core biopsy. The sensitivity of these diagnostic procedures is 
lower in dense breast tissue, in particular among pregnant and lactating women [49-51]. 
In Sweden, national guidelines for breast cancer care recommend that treatment for each 
breast cancer patient is decided at a multidisciplinary conference [52]. Factors determining 
treatment decision include clinical and pathologic characteristics of the tumour, such as 
patient’s age, comorbidity, tumour size, spread, grade and hormone receptor status. 
Locoregional treatment options include surgery (mastectomy or breast conserving surgery; 
sentinel node and/or axillary lymph node dissection) and radiation therapy. Systemic 
treatments include different combinations of chemotherapy, hormonal and targeted therapy. 
From 2014, the national guidelines [52] include a special section on treatment of pregnant 
women. Since these patients are rare, they are often referred to specialised central clinics. 
Treatment of pregnant women is highly individualised in consideration of potential risks for 
the foetus and mother [50, 53-56]. The management of each patient is optimised via close 
collaboration between the surgeon, oncologist and obstetrician. Some treatments are 
contraindicated (not given) during pregnancy due to toxicity, e.g. certain hormonal treatments 
and chemotherapies. The clinical management of pregnant women has changed over time. 
Previously, the delivery was often induced prematurely followed by initiation of treatment. 
However, in recent years the treatment of pregnant women has become more aggressive with 
pregnancy maintained until term, and chemotherapy given also during the second and third 
trimesters. A lactating woman diagnosed with breast cancer will stop breastfeeding, and 
treatment will commence shortly after the cessation of lactation. With inconclusive results, 
few studies to date have investigated treatment delays in pregnant women, but the findings 
indicate that treatment delays, if any, are small [57].  
1.2 PREGNANCY AND BREAST CANCER 
1.2.1 Pregnancy-associated breast cancer (PABC) 
Pregnancy-associated breast cancer (PABC) is commonly defined as a breast cancer detected 
during pregnancy or within one or two years of delivery. Approximately 7% of all breast 
cancers below 45 years in Sweden are detected during pregnancy or up to two years after 
delivery. PABC is most frequent in ages 30-39 years, while the proportion of PABC is 
highest in ages 25-34 years where around 25% of all breast cancers are PABC (Figure 1.2). 
Since women with PABC are exposed to a (recent) pregnancy at the time of breast cancer, the 
age-specific incidence of PABC is directly linked to the age-distribution of pregnant women.  
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Figure1.2 Numbers of PABC and non-PABC by age at diagnosis, Sweden 1990-2002. The 
percentage on the top of each bar represents the proportion of PABC [1]. 
 
PABC=BC during pregnancy or within 2 years of delivery 
Non-PABC=BC in nulliparous women or >2 years of delivery 
 
The incidence of PABC has increased over calendar time [1]. On average 30 to 40 cases are 
diagnosed per year in Sweden, and the incidence is lower during pregnancy, somewhat 
increased during the first year post-delivery and higher during the second year post-delivery 
(Figure 1.3). Interestingly, the risk pattern of pregnancy-associated cancer in relation to 
timing of delivery differs between breast cancer, malignant melanoma and cervical cancer 
(the three most common cancers in women below 45 years), which could indicate differences 
in detection and/or underlying risk [58]. 
Time-trends of pregnancy and age-at-first-birth 
Birth rates vary across time and populations. In Sweden, there are around 100,000 deliveries 
per year, with a striking trend of postponed childbearing. From 1977 to 2012, the mean age at 
first birth among mothers increased from 24.4 to 28.4 years (Figure 1.4) [59]. The majority of 
biparous women get the second child within three years of the first child, and the interval 
between first and second birth has decreased slightly over time [60]. Since women continue 
to postpone childbearing to older ages, it is more likely that their pregnancies coincide with 
breast cancer. Thus, the incidence of pregnancy-associated breast cancer is expected to 
continue to increase in future. 
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Figure 1.3 Standardised incidence ratio (SIR) of cancer detected during different trimesters of 
pregnancy and 0-6, 6-12 and 12-24 months post-delivery for breast cancer, malignant melanoma and 
cervical cancer, Sweden 1963-2007 [58].  
 
Figure 1.4 Mean age at childbirth of mothers in Sweden 1973-2012 [59].  
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1.2.2 Risk pattern of BC up to ten years post-delivery 
The observed risk pattern for breast cancer around delivery has a striking shape, with lower 
risk during pregnancy and a small increase the second year after delivery [58, 61-63] (Figure 
1.3). There is also a transient risk occurring 5-10 years after delivery [64-71], which in some 
studies has been restricted to uniparous women only [68, 69]. 
Numerous studies on childbearing and breast cancer risk have examined age-specific 
incidence (rather than risks by time-since-birth), and estimated how the age-specific 
incidence changes by each pregnancy [72-82]. However, few studies have acknowledged that 
the two timescales age and time-since-birth should be assessed and presented together [83]. 
Hence, two different bodies of literature exists which both try to address the same question, 
namely what is the effect of pregnancy on breast cancer risk. An additional challenge is the 
effect of age-at-first-birth (or age at any birth), which cannot be adjusted for in a model 
including both age and time-since-birth due to collinearity [68, 79]. 
Modifiers of the risk pattern: parity, age, family history  
One of the challenging questions concerns the underlying mechanisms for the observed risk 
pattern around delivery, and the possible modifying role of other risk factors, such as parity, 
age and family history of BC.  
Since the breast tissue undergoes temporary and permanent changes following each birth, 
studying how the risk pattern varies by time since first, second and third pregnancy may shed 
light on this question. Two Norwegian studies have found evidence of a transient risk 
following the first birth, but not subsequent births [68, 69]. The risk pattern close to 
pregnancy (within one or two years of delivery) appears not to be affected by age [61], 
whereas the transient risk 5-10 years is affected by age and is most pronounced in older 
women of childbearing age [68].  
Family history of BC has been examined in relation to time-since-birth in four large studies 
[84-87] of which one included the pregnancy window [87], with somewhat inconclusive 
results. Women with a family history of breast cancer have been suggested to harbour pre-
malignant cells at young age and may be affected by pregnancy differently compared to 
women with no family history. Hou et al [87] found that the risk was increased during and 
within 2 years of pregnancy in women with compared to without a family history, but no 
difference in risk was found further away from delivery. Wohlfahrt et al [86] found that there 
was no different risk pattern in women with a family history with the possible exception of an 
increased transient risk 5-10 years post-delivery in uniparous women with a family history. 
Results from Albrektsen et al [84] and Hemminki et al [85] are more difficult to interpret, 
partly because of choice of reference groups, but Hemminki et al concluded that there was no 
modifying effect of family history.  
With inconclusive results, few studies have assessed BRCA1/2 carriers in women diagnosed 
during pregnancy [87-89]. Hou et al [87] reported that 25% of women diagnosed with PABC 
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were BRCA1/2 carriers, compared to 11.5% among non-PABC. One study assessed mortality 
in BRCA1/2 carriers with PABC and found no increased mortality compared to non-PABC 
carriers [90].  
Although not within the scope of this thesis, it is also of relevance to assess pregnancy 
characteristics in relation to breast cancer risk, e.g. multiple births, birth weight and 
pregnancy complications as indirect markers of hormonal exposures during pregnancy. While 
several studies exist in relation to post-menopausal breast cancer [91, 92], data on pregnancy 
characteristics and pre-menopausal BC remain sparse.  
1.2.3 Tumour characteristics in BC around pregnancy 
Assessment of tumour characteristics in patients diagnosed during and shortly after delivery 
is of importance to improve the understanding of underlying mechanisms for patterns of risk 
and prognosis in these patients.  
Results from several studies suggest that tumours diagnosed during or within one or two 
years of a pregnancy exhibit particularly poor prognostic characteristics, i.e. advanced TNM 
stage, high grade and hormone receptor negativity [93-111]. Most studies have reported no 
difference in Her2 status between PABC and non-PABC tumours [95, 96, 98, 100, 108, 110]. 
However, a few studies have found increased proportions of triple-negative and Her2 positive 
non-luminal tumours in women with PABC compared to non-PABC [95, 107, 108].  
Contrary, evidence suggests that tumours diagnosed two to ten years post-delivery are more 
similar to tumours in nulliparous women. However, several investigators have reported 
increased nodal involvement also in women diagnosed with BC up to 10 years post-delivery 
[70, 102, 108, 112, 113], and two studies reported more advanced T stage [70, 112]. Most 
studies have found no evidence of differences in ER or PR status in tumours diagnosed 2-10 
years post-delivery compared to tumours in nulliparous women [102, 107-109, 112-114]. 
Similarly, some studies have reported no difference in grade between tumours detected 2-10 
years post-delivery and tumours among nulliparous women [94, 113, 114], while a few 
studies reported more high grade tumours in women diagnosed 2-10 years post-delivery [70, 
102, 112]. 
1.2.4 Prognosis following BC around pregnancy 
Several studies have observed a poorer prognosis among women diagnosed with PABC 
compared to women with non-PABC and of same age [95-104, 106, 107, 112, 113, 115-121], 
including a meta-analysis from 2012 that yielded a pooled HR of 1.44 (95% CI: 1.27-1.63) 
for PABC compared to non-PABC [122]. In some studies the poorer survival remained after 
adjustment for TNM stage and/or molecular markers [99, 101-103, 106, 107, 112, 113, 117, 
123, 124], while in other studies no difference in survival was observed after adjusting for 
TNM stage, grade and/or molecular markers [95, 96, 98, 100, 105, 121]. Since women with 
PABC appear to have a worse prognosis compared to non-PABC, it is of importance to 
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understand the possible role of delays in diagnosis, in particular in relation to how close to the 
delivery the tumour was detected.  
In studies which assessed two to ten years post-delivery, several found an increased mortality 
in women diagnosed up to 5 or 10 years post-delivery compared to nulliparous or parous 
women diagnosed >10 years after delivery [103, 112, 113, 115, 116, 124]. In one study [112] 
the poorer survival remained in women diagnosed 2-5 years after delivery following 
adjustment for tumour stage and biology, while in three studies [103, 113, 124] there was no 
difference in survival after adjustment for tumour characteristics (although hazard ratios were 
slightly elevated in one study [113]). 
1.2.5 Physiology and mechanisms 
Physiology and hormonal regulation of the breast tissue 
The breast consists of glandular (epithelial) tissue, fat and stroma, and undergoes several 
developmental phases during a woman’s life course. The epithelial tissue is found in the ducts 
and the lobes. About 80% of invasive breast carcinoma is ductal and around 15% is lobular, 
while the remaining tumours occur in other parts of the breast [125]. The development of the 
breast tissue is hormonally regulated, mainly by estrogen, progesterone, prolactin and 
different growth hormones in a complex interplay. During puberty increasing levels of 
estrogen from the ovaries (menstrual cycle) trigger the stem cells and affect the growth and 
branching of the ducts and lobes. The stroma is also affected, mainly via progesterone [126]. 
However, it is not until pregnancy that the final lobuloalveolar development and cell 
maturation occurs to prepare the breast for lactation (Figure 1.5).  
Under the influence of hormones produced by the placenta, the glandular breast volume 
increases substantially during pregnancy in a remodelling process transforming the breast into 
a mature secretory organ [126]. In late pregnancy, levels of estrogen are increased one 
hundred fold compared to levels during the menstrual cycle, and progesterone levels are 20 
times higher. During the second trimester, cell maturation (differentiation) occurs within the 
alveoli and ducts. These developments are less pronounced in women who deliver preterm. 
After delivery the estrogen and progesterone levels, which block lactation, drop rapidly 
following the expulsion of the placenta. The levels of prolactin are increased and lactation 
commences. Prolactin has a complex role and may also stimulate cell proliferation and 
turnover during lactation, with levels decreasing with duration of breastfeeding. During 
breastfeeding levels of oxytocin are also elevated [126]. 
After lactation the breast undergoes involution, an inflammation-like process with apoptosis 
similar to wound-healing, and resumes it pre-pregnancy resting state. This tissue-changing 
process has been suggested to be tumour promoting [127]. After lactation the breast density, 
i.e. the amount of glandular tissue, is lower than in the nulliparous breast [128]. There is also 
a dose-effect; for each subsequent pregnancy breast density becomes lower [129]. 
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Other permanent post-pregnancy changes in the breast include more differentiated epithelial 
cells, fewer stem cells and changes in estrogen responsiveness of the epithelial tissue [130, 
131]. These permanent changes are believed to protect against breast cancer, and parity has a 
long-term protective effect on post-menopausal breast cancer risk.  
The most pronounced changes in the breast tissue occur during the first pregnancy, but also 
subsequent pregnancies will affect the breast both temporarily and permanently [126]. It 
remains unknown how long the temporary changes may influence the breast cancer risk 
pattern, and if the influence of transient changes is different if a woman previously has given 
birth. 
The last phase of breast development is the post-menopausal involution, which occurs as a 
result of depletion of estrogen from the ovaries, and leads to replacement of glandular tissue 
with fat. 
Figure 1.5 Changes in the breast tissue during pregnancy and lactation. 
 
Mechanisms  
Physiological changes during pregnancy and lactation could be tumour initiating and/or 
tumour promoting. The changes in hormonal and immunological milieu during pregnancy 
and lactation could influence the promotion or suppression of certain tumour types 
differently. Women with a genetic pre-disposition (who should have a higher probability of 
harbouring pre-malignant cells at a young age) may be more vulnerable to pregnancy-
associated physiological changes.  
A recent hypothesis suggests that the involution of the breast tissue after lactation include an 
inflammation-like process in the micro-environment surrounding the epithelial tissue that 
could promote growth of pre-malignant cells [127]. However, the lag time between exposure 
and effect must be considered; e.g. how long would it take from an exposure to involution (or 
pregnancy) until a tumour would be detectable? 
The increased breast density associated with the physiological changes related to pregnancy 
could also lead to masking of tumours and delayed detection/diagnosis, either by patient’s or 
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doctor’s delay (signs and symptoms may be misinterpreted) or by lower sensitivity in 
diagnostic procedures (mammography, palpation, ultrasound, biopsy). Tumour lumps may be 
mistaken for normal irregular tissue changes associated with pregnancy. Given that different 
subtypes exhibit different aggressiveness, it remains unclear if such a delay would affect all 
subtypes equally. 
A tumour-promoting mechanism would lead to more aggressive tumours, while delayed 
diagnosis would lead to more advanced tumours at detection, but not necessarily more 
aggressive tumours (if the delay is equal by subtype). 
Women with pre-malignant disease may also be at higher risk for spontaneous abortions or 
have lower fertility, which would lead to reverse causation in studies of breast cancer risk in 
association with pregnancy. Women who become pregnant may also have lower prevalence 
of risk factors for developing breast cancer, i.e. a “healthy mother effect”. 
1.3 PREGNANCY-ASSOCIATION (PA) AND TIME-SINCE-PREGNANCY 
Throughout this thesis the term pregnancy-associated breast cancer (PABC) is used, which is 
not a strict definition in the literature. Some studies of PABC have only included the 
pregnancy period, while other studies have included the lactation period or used a time-point 
(e.g. 6 months, 1 year, 2 years) after delivery as the upper limit. The definition each author 
uses is often related to the specific patient group under study. For example, in terms of 
treatment, there is no point in differentiating between women diagnosed 6 months or 2 years 
after delivery, while in terms of risk, there may be a rationale for separating the time 
windows. (To complicate things further, some studies do not include the pregnancy window, 
and only evaluate time-since-delivery. Typically, these studies are not using the term 
pregnancy-associated at all but instead use time-since-delivery.) 
Theoretically, pregnancy-association (PA) is a dichotomy where the timescale time-since-
pregnancy has been divided into two groups: PA (e.g. during pregnancy and within 2 years of 
delivery) and non-PA (e.g. before pregnancy or after 2 years after delivery). PA is related to 
any woman who is exposed to a pregnancy, whereas PABC are women with breast cancer 
occurring within that PA-window, i.e. breast cancer cases exposed to (recent) pregnancy. 
Time-since-pregnancy may also be categorised into several segments of time (1st trimester, 
2nd trimester, 3rd trimester, 0-6 months post-delivery, 6-12 months post-delivery, and so on). 
The timescale time-since-pregnancy has no upper limit. 
The purpose of the PA definition is to capture the acute effects of pregnancy. The effects of 
pregnancy may however extend beyond two years, which is why some authors have proposed 
an extended risk window up to 5 or 10 years post-delivery [132]. In the papers of this thesis, 
we try to restrict the term PABC to cases diagnosed up to 2 year post-delivery and use time-
since-pregnancy for women diagnosed with breast cancer further away from delivery. 
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Since PA is a measure of pregnancy exposure, any factor associated with pregnancy may be a 
confounder of associations between PA and an outcome (e.g. breast cancer, survival), if it is 
also associated with the outcome (age being the most obvious example). 
Pregnancy-associated BC is not the same as pregnancy-caused BC, but rather it merely 
means that the BC is diagnosed near (or in association with) a pregnancy. One outstanding 
issue is what we mean by “near”, and how to classify these cancers in a useful way for 
epidemiological and clinical purposes. 
For nulliparous women the timescale time-since-pregnancy is not defined. Instead, they 
follow other timescales, such as age or calendar time. The combined group non-PABC (i.e. 
women diagnosed prior to pregnancy or more than 2 years after delivery) is therefore a 
mixture of nulliparous women (without any childbirth) and women with a previous (not so 
recent) childbirth. Depending on the research question, it is sensible to keep these two distinct 
groups together or apart. 
Time-varying exposure and time-varying effect 
In theory, time-since-pregnancy could be a proxy for (at least) three different phenomena: 
1. Exposure (time-varying exposure); e.g. changing exposure levels during pregnancy or 
lactation (whereas parity would reflect permanent/constant changes after pregnancy) 
2. Detectability (time-varying ascertainment); e.g. masking of tumours due to changes in 
breast 
3. Effects (time-varying effects); e.g. effects that vary by time-since-pregnancy, either as 
an effect of constant or of time-varying exposures 
Thus, an estimate of a decreased risk during pregnancy can reflect either an effect (3) of 
lower exposure levels (1) or an effect of lower detectability (2). An increased risk after 
delivery can reflect either an acute effect (3) of lower exposure levels (1) after delivery, or a 
delayed effect (3) of previous exposure levels (1), or an increased detectability (2). We 
cannot, without information on other variables, determine which of these phenomena we 
capture in our effect estimates in different risk windows following pregnancy. The issue of 
lag time between exposure and effect must also be taken into account when interpreting time-
dependent effects by time-since-pregnancy. 
Lastly, it is important to realise that a woman’s parity changes with every childbirth, and is a 
time-varying factor per se through her reproductive period. A woman who is nulliparous at 
one point in time may have had three children at a later point in time. In reality, she will 
follow three timescales: time-since-first-pregnancy, time-since-second-pregnancy and time-
since-third-pregnancy. In studies I-IV, the term time-since-pregnancy refers to time-since-
latest-pregnancy. 
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1.4 UTILISING REGISTERS TO STUDY PREGNANCY AND CANCER 
1.4.1 Strengths 
All studies included in this thesis are based on data from Swedish national health and 
population registers. Using individual level record linkages between registers via the personal 
identification number (personnummer, PIN), we generated nationwide cohorts reflecting the 
situation in the general population, and patients from the general population, and not 
restricted to selected patient groups.  
PABC is a rare disease which requires long study periods or large populations at risk to 
accrue sufficient number of cases for statistical power. To study PABC, information is 
needed on both pregnancies and breast cancers. The possibility to combine information from 
the Swedish Cancer Register with information on pregnancies from the Multi-Generation 
Register to identify risk periods around childbirth for each woman is one of the key strengths 
of the studies in this thesis. Similar studies are only possible to conduct in countries with 
linkable population-based registers, and the reason why several key references in this field are 
from Sweden, Norway and Denmark. 
Since the full population can be enumerated, it is also possible via appropriate study designs 
to select smaller samples and still obtain estimates of incidence, risk, prevalence and survival 
applicable to the full population, and not just relative effect measures.  
1.4.2 Limitations 
Register-based epidemiological research has several limitations. While a long follow-up is a 
powerful feature of a register-based study, it also associated with challenges that potentially 
can affect the interpretation of results, including changes in population structure over time, 
age trends, changes in inclusion criteria and disease classification over time. In addition, 
improvements in diagnostic methods (affects incidence) and treatments (affects survival) 
change over time. Hence, historic cases may not be representative of recent cases, which 
could influence the interpretations of the findings. The relevance of historic data depends on 
the purpose of the study; e.g. to study trends over time or to provide advice to clinicians. 
National cancer registers typically do not include very detailed information (few variables). 
Hence, the data resolution limits the possibilities to assess research questions in detail. In this 
thesis we try address this issue by using information from Breast Cancer Quality Registers, 
which include more detailed clinical information (study IV).  
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2 AIMS 
The overarching aim of this thesis was to examine how the time-since-pregnancy affects the 
short-term breast cancer risk, tumour characteristics and survival following breast cancer.  
Specific aims were to study: 
1. Patterns of breast cancer risk in different time-windows during and up to ten years 
after pregnancy, and whether family history of breast cancer modifies the risk pattern 
around pregnancy (study III). 
2. If tumour characteristics differ in women diagnosed with breast cancer during or 
shortly after pregnancy compared to women diagnosed not near a pregnancy (study II, 
IV). 
3. If women diagnosed with breast cancer near a delivery have a poorer prognosis 
compared to women diagnosed not near a pregnancy, and if the prognosis depends on 
the proximity of diagnosis to delivery (study I, IV). 
4. If adverse tumour characteristics can explain the poorer prognosis observed in women 
diagnosed with breast cancer during or shortly after pregnancy (study II, IV). 
5. To utilise recently developed statistical and epidemiological methods to elucidate the 
complex associations between time-since-pregnancy, breast cancer incidence and 
survival. 
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3 MATERIAL AND METHODS 
All studies (I-IV) were based on data from national health and population registers, which can 
be linked by use of the individually unique personal identification numbers (PIN, 
personnummer) assigned to Swedish residents [133, 134]. This way, large population-based 
cohorts with information on exposures, outcomes and confounding factors were created. 
3.1 DATA MATERIAL 
3.1.1 Register linkages to create study populations 
In all studies (I-IV), the study populations were based on women identified in the Swedish 
Multi-Generation Register (MGR). Information on childbirths, cancers, death, migrations and 
confounders was obtained from relevant registers. 
Study I was based on a register linkage of women followed for breast cancer up to 2002, 
whereas studies II-IV used an updated register linkage including women followed for breast 
cancer diagnoses up to 2009 (Figure 3.1). 
Figure 3.1 The register linkage used in study I, including women and births in the MGR for years 
1961-2002 (left). The updated linkage used in study II-IV, including MGR data up to 2009 and 
additional cancer information on sisters and mothers, and breast cancer quality register information 
(right). 
 
* The study population included women who were mothers to index persons (=children) in the MGR. 
** The study population included women who were index persons in the MGR. 
SCR=Swedish Cancer Register; MGR=Swedish Multi-Generation Register; CDR=Swedish Cause of 
Death Register; BCQR=Breast Cancer Quality Register 
 
3.1.2 The Multi-Generation Register (MGR) 
The Swedish Multi-Generation Register (MGR), held at Statistics Sweden (Statistiska 
centralbyrån), includes individuals (index persons) born in Sweden from 1932 and residing in 
Sweden at any time from 1961 and onwards [135]. The register is based on data from the 
population registration (folkbokföringen) and includes links between the index persons and 
their parents (biological and adoptive). The MGR provides links between a mother and her 
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children (liveborn) and information on dates of childbirths. Since the register holds multiple 
generations, index persons can also be parents to other index persons. However, among 
foreign-born index persons born before 1990 the proportion of identified parents is lower 
(around 20-40%), as is among index persons who died prior to1991 (around 60% have 
identified parents). 
In study I, the study population was defined as women who were mothers to index persons 
(children) in the MGR. These women could be born prior to 1932, but we restricted to 
women born 1925 or later. Of note is that the study population represented women who were 
registered as residents in Sweden at any time from 1925 or later, and alive in 1961 or later. 
Women born 1925-1931 and with no record of children in the MGR were also included, since 
the MGR copy at Statistics Sweden also includes these women. Women born after 1932 and 
alive in 1961 (the majority of women in the study population) were also index persons in the 
MGR.  
In study II-IV, the study populations were based on women who were index persons in the 
MGR, with children who also were index persons in the MGR. All these women were 
therefore born 1932 or later and alive from 1961 or later. 
3.1.3 The Swedish Cancer Register (SCR) 
The Swedish Cancer Register (SCR) includes newly diagnosed primary tumours in Swedish 
residents since 1958 [3, 136]. The data are recorded at six Regional Cancer Centers (RCC), 
and compiled into a national register at the National Board of Health and Welfare. Reporting 
of malignant (and some benign) tumours to the register is mandatory by law and the 
completeness of solid tumours is deemed high (>98% for BC tumours) [137, 138]. 
Essentially 100% of breast cancer tumours in women below 45 years are morphologically 
verified by a pathologist [3]. A limitation of the SCR is that tumours reported by death 
certificate only (DCO) are not included or traced. For breast cancer in young patients this 
limitation is negligible, since the absence of death certificate initiated cases has a greater 
impact on cancer sites likely to be diagnosed at old age or autopsy.  
The SCR includes information on PIN, tumour site, histology, means and date of diagnosis 
and hospital of diagnosis. Tumour site is coded with the current version of the International 
Classification of Diseases (ICD-O-2) and also translated to ICD version 7 for all years to 
facilitate comparisons over time. Since 2004, information on tumour spread (TNM stage) is 
included for the majority of tumour sites, and is a mixture of clinical and pathologic TNM 
stage [37]. For BC tumours, data on TNM stage is available from 2002 (Figure 3.2).  
By combining information in the Swedish Cancer Register with the structure of the MGR, we 
obtained information on family history of breast cancer (i.e. breast cancer in mother and 
sisters to the index women). 
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Figure 3.2 Availability of TNM information in the SCR 2000-2009 for women with a first BC aged 15-
44 years (study II). 
 
 
3.1.4 The Breast Cancer Quality Register (BCQR) 
The National Breast Cancer Quality Register (BCQR) on the web platform INCA includes 
primary breast cancer tumours (invasive and in situ) diagnosed since 2008 [139]. The INCA 
platform is managed jointly by the six Regional Cancer Centers (RCC). Incident cases are 
reported via the six RCCs, using nationally uniform variables and coding. Before 2008, 
reporting was made to six regional registers with slightly different content. The first regional 
register started in 1976 (Stockholm-Gotland). From 1992, all regions reported to separate 
registers which together had national coverage. Contrary to the SCR, reporting to the BCQR 
is not mandatory by law (patients may opt-out). In comparison to the mandatory reporting to 
the SCR, 98.9% of tumours were also recorded in the BCQR in 2014 [139].  
The primary purpose of the BCQR is evaluation of quality of care. The register includes 
detailed clinical information regarding diagnosis, tumour characteristics and treatment, for 
example information on date of diagnosis, TNM stage (clinical and pathologic), histology, 
grade and molecular markers such as ER, PR, Her2 and Ki67. 
The BCQR was used in study IV including diagnosis years 1992-2009. For years 1992-2007 
historical data from regional registers was used, while standardised INCA variables were 
used for years 2008-2009. We contacted each region separately, with a pre-specified study 
protocol of variables and codes. Each region compiled a dataset based on their local register. 
Prior to 2008 there were local differences in interpretation of the protocol, variable 
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availability, contents, codes and completeness. An effort was made to complete the data after 
contact with the regions. If the data quality was still low, the region was excluded from the 
analyses of specific variables.  
3.1.5 Death information 
Mortality data has been recorded in Sweden since 1751 [140]. Since 1961, digitalized 
information on deaths and causes of deaths is available in the Swedish Cause of Death 
Register (CDR) held at the National Board of Health and Welfare. There is also a digitalised 
register for the years 1952 to 1960. The CDR includes information on deaths of Swedish 
residents who die in Sweden or abroad, including variables PIN, date of death, place of 
residence, underlying cause of death and contributing causes of death. The completeness is 
virtually 100%. However, 2.6% of registered deaths in 2014 lacked information on 
underlying cause of death (increased from 0.5% in 1975) mainly reflecting increased age at 
death and declining autopsy rates over time [140]. 
3.1.6 Migrations 
Information on migrations in and out of Sweden are recorded in the Total Population Register 
(TPR) held at Statistics Sweden [141]. Data on immigrations are available from 1969 and on 
emigrations from 1961, including dates of migration, type of migration (immigration or 
emigration) and PIN. In studies I-IV, emigration information from 1969 was included. 
3.1.7 Education information 
Continually updated information on highest achieved educational level for Swedish residents 
is recorded in the Education Register since 1985 [141]. All schools and universities in 
Sweden report to the register. Educational level was also recorded in the Censuses 1970 
(Folk- och bostadsräkning, FoB 70) and 1990 (FoB 90). The registers include information on 
PIN, current highest educational level (using a standardised coding system, SUN) and place 
of education.  
3.1.8 Ethical considerations using register data 
The use of population and health registers for research is governed by Swedish law, mainly in 
The Public Access and Secrecy Act (Offentlighets- och sekretesslagen), the Ethical Review 
Act (Etikprövningslagen) and the Personal Data Act (Personuppgiftslagen). Register 
information under secrecy may be used for research if the study has been approved by an 
Ethical Review Board and if the register holder approves the data extraction [142, 143]. The 
secrecy is transferred to the research organisation, in this case Karolinska Institutet. All 
studies in this thesis had an ethical approval, and use of the data was approved by Statistics 
Sweden, the National Board of Health and Welfare, and each RCC which held the regional 
versions of the BCQR. 
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Register data for research purposes may be used without the knowledge of each registered 
individual. Before data delivery and analysis, directly identifying information such as name 
and PIN is removed and replaced with a randomly generated sequence id (löpnummer). 
Published results must also protect the integrity of the registered individuals. 
3.2 MEASUREMENTS, ASCERTAINMENT AND DATA QUALITY 
3.2.1 Childbirths: Parity, PABC, time-since-pregnancy (main exposure) 
Childbirths to each woman were identified using information in the MGR, with the limitation 
that only liveborn children are included in the MGR. Thus, pregnancies leading to 
miscarriage, stillbirth or elective abortion were not captured. Childbirths occurring outside 
Sweden will be recorded if the woman is a Swedish resident or immigrates to Sweden. 
Another approach to identify childbirths is to use the Medical Birth Register (MBR). The 
MBR includes liveborn and stillborn children from gestational week 22, but no fetal loss prior 
to week 22. Since the stillbirth rate is very low and the majority of fetal losses occur prior to 
week 22, the use of the MBR would identify only few additional pregnancies for the purpose 
of these studies. There is a slight discrepancy between childbirths in the MGR and MBR, 
with 1-3% fewer births included in the MBR [59, 144]. 
Pregnancy-associated breast cancer (PABC) 
In studies I-IV, pregnancy-associated breast cancer (PABC) was defined as a breast cancer 
diagnosed during pregnancy or within two years of delivery of a liveborn child (Figure 3.3). 
Thus, women who were pregnant at time of diagnosis and had a miscarriage, stillbirth or 
elective abortion were misclassified as non-PABC. Women with non-PABC were either 
nulliparous at diagnosis or had a breast cancer more than 2 years after delivery. Since no data 
on estimated conception date is available in the MGR, the pregnancy period was defined for 
all women as 9 months prior to the child’s birthdate. Thus, the pregnancy period is 
approximate and does not account for preterm or postterm births.  
Figure 3.3 Pregnancy-association (PABC window) and time-since-pregnancy (TSP). 
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Time-since-pregnancy (TSP) 
Similarly, time-since-pregnancy was defined as risk windows starting from 9 months prior to 
delivery date of a liveborn child, and 0-3, 3-6, 6-12, 12-24 months, 2-5, 5-10 years (3-4, 5-6, 
7-8, 9-10 years in Study III) after birth (Figure 3.3). This definition also misclassifies women 
with miscarriage, stillbirth or elective abortion.  
The window 0-6 months post-delivery broadly represents women who breastfeed, while the 
window 6-12 months represents a period of partial breastfeeding, and the window 12-24 
months represents a period during which breastfeeding is uncommon. There is no register 
data on breast feeding, but a survey from 2008 reported that 89% of mothers breastfed (fully 
or partly) at 2 months, 67% at 6 months, 37% at 9 months and 17% at 12 months [145]. 
Comparison group: Nullipara or non-PABC? 
When studying the impact of current or recent pregnancy (within 2 years) on BC risk and 
prognosis, the comparison group (unexposed women) would ideally be nulliparous women 
with no previous childbirth. However, in studies of PABC it is common to combine 
nulliparous women with parous women with a delivery more than 2 years ago, into the 
combined group “non-PABC”.  
Since nulliparous women tend to be younger than parous women (the likelihood to have had 
children increases with age), a comparison group including only nulliparous will be younger 
than the combined non-PABC group. A second challenge is that the risk and survival of BC 
may differ between nulliparous and parous women (>2 years since delivery). For example, 
older nulliparous women may to a higher extent represent women with fertility problems 
which could be linked to BC risk. 
The second challenge is not overcome by using women with non-PABC as the comparison 
group, since women with non-PABC are likely to represent a mix of different risk groups. A 
comparison to nulliparous may yield stronger effects, than a comparison to the mix of 
high/low risk groups in non-PABC. In studies II and IV, we therefore included comparisons 
with both a non-PABC group and a nulliparous group (similar to other studies which have 
used both comparison groups). In study I, the PABC group was compared to the non-PABC 
group, while in study III time-since-first-birth was compared to nulliparous women. 
Other issues 
The most recent birth was used as the index birth for both PABC and TSP definitions; if two 
births occurred within the PABC window, then the latest birth was used as the index birth. 
Similarly for time-since-pregnancy, following an additional birth the woman jumped back to 
the pregnancy window and started counting time from the most recent birth.  
Twin pregnancies were counted as two childbirths and included in the parity variable in study 
I-IV, but not given additional attention since the rate of twinning was too low to have an 
impact on the effect estimates of PABC and time-since-pregnancy. 
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While the SCR started in 1958 and the MGR in 1961, only breast cancers from 1963 were 
included in study I and III in order to capture all PABC up to 2 years post-delivery (birthdates 
of children were only recorded from 1961). During 1961-1962 it was not possible to properly 
classify PABC up to 2 years post-delivery, since childbirths must have occurred prior to 
1961. 
In study I and II, parity was defined as number of childbirths prior to the index birth related to 
the PABC. Thus, parity did not reflect the actual parity of the woman, but rather the 
reproductive history of the breast tissue prior to the most recent birth (i.e. how many previous 
childbirths the tissue had been exposed to). In study III and IV, parity was defined as current 
parity, counting the index birth and pregnancy window into the parity. 
3.2.2 Breast cancer and tumour characteristics 
In all studies, BC was defined as the first primary cancer for each woman recorded in the 
SCR which was an invasive breast cancer. Invasive breast cancer was defined as ICD version 
7 code 170 and patho-anatomical diagnose (PAD/C24.1) code 096 (adenocarcinoma) [146]. 
Women who had any cancer (breast or any other type) recorded in the SCR prior to age 15 
were excluded. Also, women with a second cancer occurring after the first breast cancer were 
censored at time of the second cancer. The reason for these exclusions was to study risk and 
survival in a group of patients with no previous experience of cancer which could potentially 
influence future risk, management and prognosis. The risk of contralateral BC is increased in 
women with a previous breast cancer [147].  
Since pre-menopausal BC exhibits different risk and prognostic factors compared to post-
menopausal BC, age at diagnosis was restricted to 45 years, a cutoff which should ensure that 
most BC cases were pre-menopausal [148]. 
In study IV, a total of 71 malignant tumours according to the SCR were recorded as non-
invasive (in situ) in the BCQR. For these cases, the information from SCR was used as the 
truth and all cases were deemed invasive. 
TNM stage in the SCR  
Study II used information on TNM stage from the SCR in years 2002-2009, which is a mix of 
clinical and pathologic TNM stage. About 2/3 of women had a record of clinical TNM stage 
and 1/3 had pathologic TNM stage [97]. Although clinically based assessment of TNM is a 
less precise measurement, there was no difference in type of TNM assessment (clinical or 
pathologic) for PABC and non-PABC cases. Hence, any misclassification of TNM stage is 
likely to be non-differential with respect to PABC status and will attenuate the effect 
estimates towards the null.  
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TNM stage in the BCQR 
Study IV used both clinical and pathologic TNM stage information from the BCQR. Because 
of regional differences in completeness, some regions were excluded from each T, N and M 
component in the final analysis. 
ER, PR, Her2, grade status in the BCQR 
Study IV used information on tumour markers available in the BCQR. Estrogen receptor 
(ER) and progesterone receptor (PR) status were defined as positive or negative using cut-
offs according to current national guidelines for breast cancer care [52] and local guidelines at 
each laboratory. Her2 was defined as positive if amplified, otherwise negative or missing if 
not assessed. Grade was assessed according to the Nottingham Histological Grade (Elston 
grade) into the three levels (grade I, grade II, grade III). Information on ER and PR was 
available in all regions (in four regions from 1992, and in two regions from 2000 and 2003, 
respectively). Information on Her2 was available in all regions (from 1999 in the earliest 
region and from 2007 in the latest). Information on grade was available in all regions (from 
1995 in the earliest and from 2008 in the latest region). The pattern of data availability over 
year and region was similar for women with PABC and non-PABC.  
Treatment variables in the BCQR 
Planned treatments, such as type of surgery, neoadjuvant and adjuvant treatment, are recorded 
in the BCQR. In study IV, information on surgical treatment (mastectomy or breast 
conserving surgery, BCS) was available for more than 90% of the women. However, regional 
variation in data availability hampered the analysis of neoadjuvant and adjuvant treatment. 
Information on neoadjuvant treatment was missing for three out of six regions, while 
information on adjuvant treatment was missing or inconsistent over calendar year in several 
regions. Adjuvant treatment was therefore not included in the final analysis.  
3.2.3 Family history of BC 
Family history of BC was defined as having a mother or a sister with breast cancer (study III, 
IV). Using the family structure of the MGR, sisters and mothers to the women under study 
were identified and assessed for a record of BC in the SCR. A woman is more likely to have a 
mother affected by BC than a sister, reflecting a longer time at risk in mothers. However, 
because of the starting years of the registers, sisters with BC were over-represented compared 
to mothers. As expected, identified mothers were more likely to have been diagnosed with 
BC at older age (mean age 60 years), while identified sisters were more likely to have BC at 
younger age (mean age 52 years).  
A limitation of the MGR is that older birth cohorts of women are more likely to lack 
information on mothers. Since sisterhood is defined based on having the same mother, 
missing information on mother also leads to missing information on sisters. Also, since 
information on mother to a higher extent is missing among immigrants, we excluded the 
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possibility to immigrate into the cohort after age 15 years to avoid misclassification of family 
history of BC (study III). 
3.2.4 Death 
Studies I, II and IV assessed survival in breast cancer patients. The outcome was defined as 
all-cause mortality, i.e. death due to any cause (including breast cancer). Nearly all deaths in 
this young patient group were recorded as due to breast cancer (90% in study I and 94% in 
study IV). Estimates of cause-specific mortality were very similar to all-cause mortality. All-
cause mortality also captures treatment related deaths, which may not be recorded with BC as 
the underlying cause of death.  
Death information from the CDR was used in study I-IV. Deaths are also recorded in the 
Total Population Register (TPR), but without the underlying cause of death. To optimise the 
completeness of the death date information, we also used information from the TPR to 
complete partially missing dates of death in the CDR (study II, III, IV).  
3.3 STUDY DESIGNS 
The choice of epidemiological study design is based on several aspects, e.g. the research 
question, target population and availability of data. All studies I-IV were population-based, 
i.e. the cases originated from well-defined populations with respect to age, calendar time and 
region. This is a key strength of the nationwide registers and the record linkages based on the 
PIN. With this approach, the total population over time can be enumerated, and disease 
estimates can be obtained not only for selected patient groups or hospitals, but rather for the 
total spectrum of patients in the population. The target population is therefore larger and the 
results from such studies can be applied to a wider range of patients and individuals. 
3.3.1 Design for studying risk patterns (case-cohort) 
The aim of study III was to estimate the incidence rate ratios (IRRs) of BC around delivery 
comparing women with and without a family history of breast cancer. This required a 
disease-free (BC free) population at risk where incident BC cases could be identified, 
together with information on childbirths and family history. 
Cohort 
Using the MGR, we identified a cohort of more than 3.5 million women aged 15 to 44 years 
residing in Sweden between 1963 and 2009. In addition, we required that a woman was free 
of any cancer prior to age 15, that she did not immigrate to Sweden after age 15, that she had 
at most 4 children at entry to the cohort, and that her follow-up was censored if she had a 5th 
pregnancy.  
The restriction to at most 4 children was due to the complicated time-splitting required to 
estimate incidence in time-windows around delivery. Despite this restriction, most data were 
used in the analysis, since more than 95% of BCs occurred in women with 4 children or less. 
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The restriction on immigration into the cohort meant that women either entered the cohort 
either in the beginning of 1963 (if born prior to 1948) or at age 15 (if born after 1948 or later) 
(Figure 3.4). 
End of follow-up occurred at one of the following events, whichever came first: date of the 
first invasive breast cancer (recorded in the SCR), date of death (information from the CDR 
and TPR), first emigration after entry (information from the TPR), end of 2009 or date at age 
45.  
Figure 3.4 Lexis diagram [149] of the study population of women (grey area) included in the incidence 
study (study III). Birthyears 1932-1994, diagnosis years 1963-2009, ages 15-45 years. 
 
 
Case-cohort 
Because of the extensive time-splitting required for estimating incidence rates around 
delivery (see section 3.4.1), we selected a case-cohort sample from the cohort to improve the 
computational efficiency. Rather than using the full cohort (where most women did not have 
BC), the data size was reduced by selecting all women with BC and a sample of women who 
did not have the event (BC-free women).  
The case-cohort design, introduced by Prentice in 1986, is a way to reduce the control 
(comparison) group while retaining the possibility to estimate rates and rate ratios applicable 
to the full cohort [150]. A case-cohort sample is drawn in two steps: Firstly, from a defined 
cohort, a random sample (subcohort) is drawn from the cohort at start of follow-up, with a 
given sampling fraction of p%. The subcohort is a smaller version of the cohort and will 
include a small proportion of cases. Secondly, all the individuals outside the subcohort who 
later become cases during follow up are added from start of follow-up to the case-cohort 
sample [151, 152]. Thus, the final case-cohort sample will include all cases in the full cohort, 
and a sample of non-cases (disease-free persons) (Figure 3.5). All persons in the case-cohort 
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sample contribute with their follow-up time to the total person-time at risk. In the analysis, 
the skewed sampling must be accounted for by use of weights in the likelihood of the 
statistical model. 
Figure 3.5 Two representations of the case-cohort design. The case-cohort sample includes a 
randomly sampled subcohort at start of follow-up (green) and all additional cases occurring outside 
the subcohort. Cases (red) are both within and outside the subcohort. 
 
 
For study III, a subcohort was drawn as a 2% random sample of the cohort at start of follow-
up (Table 3.1). Additionally, all women outside the subcohort who later had breast cancer 
(cases outside the subcohort) were added. Thus, the case-cohort sample included all BC cases 
in the cohort and a sample of BC-free women (non-cases). Since the sample size was large 
(albeit the sampling fraction was low) the loss in precision was negligible compared to the 
full cohort.  
 
Table 3.1 Cohort (n=3,452,506) and case-cohort sample (n=83,800) of study III. Shaded cells are 
included in the case-cohort sample. The subcohort sampling fraction was 1.987%. 
 Outside  
subcohort 
Inside  
subcohort 
Total  
cohort 
Non-cases 3,368,706 68,252 3,436,958 
Cases 15,213 335 15,548 
Total 3,383,919 68,587 3,452,506 
 
A key feature of the case-cohort design is that the subcohort is selected at start of follow-up 
and not at the time of the cases (as in a nested case-control design). Thus, the subcohort 
represents a control group which is not time-matched to the cases, and hence the subcohort 
can be used for several outcomes. The lack of time-matching also makes it straightforward to 
estimate absolute rates and risks from the case-cohort sample, since the subcohort gives a 
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correct representation of the total person-time at risk in the full cohort (the denominator of the 
rate) via the sampling fraction.  
An alternative to the case-cohort design is the nested case-control design. In contrast to the 
case-cohort design, the nested case-control design is time-matched (controls are selected from 
the riskset of eligible persons at the time of a case) and sampling fractions in each riskset are 
rarely retained. Hence, from a nested case-control we typically estimate incidence rate ratios 
but not absolute rates and risks. If sampling fractions in each riskset are retained it is possible 
to estimate rates and risks. However, in a situation with multiple timescales, it would be less 
straightforward to obtain sampling fractions in a time-matched design [152, 153]. The 
statistical efficiency of the nested case-control and the case-cohort designs is similar for the 
same number of non-cases (controls). Hence, the case-cohort sample of study III had a 
statistical efficiency similar to a nested case-control sample with 4-5 controls per case (which 
would give a sample of around 83,000 persons).  
3.3.2 Design for studying tumour characteristics (cross-sectional) 
Studies II and IV assessed associations between time-since-pregnancy and tumour 
characteristics at breast cancer diagnosis, using cohorts of patients with BC. Information on 
women and dates of childbirths were obtained from the MGR. 
Study II included women identified in the MGR with a record of BC in the SCR at age 15 to 
44 years between 2002 and 2009. We restricted women to be cancer-free prior to 2002, and 
only the first recorded BC during 2002 and 2009 was included. Because of the restriction of 
age and period at diagnosis, these women were born from 1957 until 1988 (theoretically 
possible up to 1994) (Figure 3.6). 
Study IV included women identified in the MGR with a record of diagnosis of BC in the SCR 
at age 15 to 44 years between 1992 and 2009. Only the first BC during 1992 and 2009 was 
included, as we restricted to women who were cancer-free prior to 1992. Because of the 
restriction of age and period at diagnosis, these women were born from 1948 until 1988 
(theoretically possible up to 1994) (Figure 3.6). Information on tumour characteristics was 
also added from the BCQR. The SCR, and not the BCQR, was used as starting point to 
identify BC patients in order to ensure that the first tumour for each woman was captured 
(tumours prior to 1992 were not included in the BCQR dataset at hand).  
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Figure 3.6 Distribution of included BC patients in each study by birth cohort (blue) and year of 
diagnosis (white). 
 
Compared to the cohort of BC patients identified in SCR (n=9441), we found a match in the 
BCQR for 9,006 (95%) women. For 6,480 (72%) of these women the diagnosis date was the 
same, for the remaining 28% the diagnosis date differed by ±90 days (the diagnosis dates 
may differ between the SCR and the BCQR, because of separate reporting). The matching 
proportion ranged between 93-99% for all years except 1992 (Table 3.2). A total of 245 
(2.6%) women had no match in the BCQR, and for 190 (2.0%) women the match in the 
BCQR was not within ±90 days of the SCR diagnosis date.  
The timing of most recent pregnancy and the tumour characteristics were both assessed at 
diagnosis of BC (no follow-up was included in the analysis). Hence, the data represented 
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cross-sectional study populations, where prevalence proportions and odds ratios (OR) can be 
estimated. Alternatively, a longitudinal (as opposed to cross-sectional) approach could have 
been used to estimate incidences and incidence ratios of subtypes of BC (an approach used by 
previous studies [70, 93, 94]).  
Table 3.2 Percentage of BC tumours identified in the SCR (n=9,441) for women aged 15-44 years in 
1992-2009, which also had a match in the BCQR (within ±90 days difference in diagnosis dates in the 
SCR and BCQR), n=9,006. 
Year of 
diagnosis 
In  BCQR 
% 
 Year of  
diagnosis 
In BCQR 
% 
1992 87.0  2001 95.1 
1993 96.9  2002 94.0 
1994 97.1  2003 94.1 
1995 95.3  2004 95.4 
1996 97.9  2005 93.4 
1997 95.4  2006 96.7 
1998 95.9  2007 95.3 
1999 94.5  2008 98.0 
2000 95.3  2009 98.9 
 
3.3.3 Design for studying mortality (cohort) 
Studies I, II and IV examined the mortality in women with BC near delivery using cohorts of 
patients with BC.  
Study I included a cohort of women identified in the MGR who also had a record of BC 
diagnosis in the SCR at age 15 to 44 years between 1963 and 2002. Only the first BC for each 
woman between 1963 and 2002 was included. The women were born from 1925 until 1980 
(theoretically possible up to 1987) (Figure 3.6); incorrectly stated in the published article 
[154] that women were born from 1948 or later. There were 1,850 women born 1925-1931, 
of which 1,486 were mothers in the MGR and 364 were nulliparous (included in the 
population registration which the MGR is based on), with cancers diagnosed 1963-1976. 
Comparing studies I, II and IV (Table 3.3), a total of 1,110 women with PABC were included 
in study I and 778 in study IV, while study II had the shortest study period including 403 
women with PABC. The maximum time of follow-up for mortality differed between the 
studies (15 years in study I; 9 years in study II; and 10 years in study IV). Study I included 
death information up to end of 2004, while study II and IV included information on deaths up 
to end of 2010. Study III, which had the longest period under study, included 1,208 women 
with PABC. 
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Table 3.3 Overview of materials used in study I-IV.  
 Study 
population 
Age 
at BC 
Year 
at BC 
Cancer 
data 
Design PABC1 TSP 
window 
Outcome 
Study I BC patients 
N=15,721 
15-44 1963-2002 
 
SCR Cohort 1,110 Preg-2y Survival up to 
15y 
Study II BC patients 
N=4,431 
15-44 2002-2009 SCR Cross-
sectional, 
Cohort2 
 
403 Preg-10y TNM stage, 
Survival up to 
9y 
Study III Women 
N=3.5 mill.  
(with BC 
n=15,548)3  
15-44  1963-2009 SCR Case-
cohort 
(cohort) 
1,208 Preg-10y Incidence 
Study IV BC patients 
N=9,441 
15-44 1992-2009 SCR 
BCQR 
Cross-
sectional, 
Cohort2 
778 Preg-10y TNM stage, 
grade, 
ER/PR/Her2, 
Survival up to 
10y 
TSP=time-since-pregnancy. Preg=pregnancy. 
1 PABC defined as breast cancer during pregnancy and up to 2 years post-delivery.  
2 Cross-sectional sample at diagnosis for assessing stage/tumour characteristics; cohort sample for 
assessing mortality. 
3 Included breast cancers in women with ≤4 children and with no immigration after 15 years of age. 
This restriction was not applied to study I, II and IV. 
 
3.4 STATISTICAL METHODS 
Survival analysis 
Cohort studies are analysed using survival analysis, which is the statistical method used to 
analyse time-to-event data and accounts for incomplete follow-up due to censoring. Each 
person contributes with a follow-up time (time-to-event) and a binary outcome (e.g. BC or 
death). 
From cohort data we estimate hazard rates, which depending on the outcome either can be 
termed incidence rates (if outcome is disease) or mortality rates (if outcome is death). The 
hazard rates can be modelled with different types of regression models, e.g. Cox regression, 
Poisson regression or flexible parametric survival models (FPM). These three models all 
yield hazard ratios (HR) as the effect measure associated with the exposure, although they are 
different in how they model the underlying baseline hazard rate [155]. In Cox regression, the 
baseline hazard rate is not estimated (semi-parametric model), while in Poisson regression 
and the FPM the baseline hazard rate is estimated (parametric models).   
3.4.1 Analysis of risk patterns (study III) 
The case-cohort study of BC risk patterns in relation to time-since-pregnancy and family 
history of breast cancer was analysed with weighted Poisson regression, with weights 
accounting for the case-cohort sampling. Weights can be applied for both Cox regression and 
parametric survival models such as Poisson regression and the FPM [151, 152, 156].  
Several weighting schemes have been proposed for the analysis of the case-cohort design 
[151, 152]. We used Borgan II weights, where each observation is weighted with the inverse 
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of the sampling fraction. For the cases, the weights were 1 (since the sampling fraction 
among cases was 100%), and for non-cases the weights were 1/0.02 (since the sampling 
fraction among non-cases was 2%; the sampling fraction of non-cases is approximately equal 
to the sampling fraction of the subcohort). Hence, each non-case in the analysed sample 
represented 50 non-cases in the full cohort. Since the case-cohort sample was large 
(n=83,800), the additional sampling error introduced by the case-cohort sampling was 
negligible and only affected the standard errors in the second or the third decimal place. 
Poisson regression was chosen because of its strength in handling multiple timescales and 
modelling of interactions with time-since-pregnancy and family history of BC. Adjustment 
for a timescale in a Poisson regression model requires that time is categorised, so-called time-
splitting. Each record will be split into a new row of data for each time interval. If the time-
splitting is fine, the dataset will rapidly expand. In study III, time was split on several 
timescales: age in 1 year intervals, calendar time in 5 year intervals and time-since-pregnancy 
in 1 year intervals. Also, parity was split into a time-varying exposure. This splitting yielded 
an enormous dataset of 60 to 80 million rows. To reduce the size of the dataset, we utilised 
the case-cohort design. The time-split dataset for analysis using the case-cohort sample of 
83,300 women included around 3 million rows of data. 
Additional birth approach (study III) 
To assess the impact of pregnancy on BC risk in study III, we estimated incidence rate ratios 
(IRRs) comparing time-since-latest-pregnancy to women with a similar reproductive history 
prior to that latest pregnancy, i.e. women of a given parity were compared to women who had 
not had the latest (additional) child (Figure 3.7). In contrast, a comparison between women of 
any parity to nulliparous women would reflect the combined effect of parity and the 
additional child, not being able to disentangle effects of previous births from the time-varying 
effect from the latest pregnancy. In combination with age-at-previous-births, the adjustment 
also included time-since-previous-births, comparing women with same number of children 
and time between births. Because of collinearity between age, time-since-pregnancy and age-
at-pregnancy (if you know the value of two of the variables, then you will know the value of 
the third), it is not possible to adjust for age at the latest birth when assessing time-since-
latest-pregnancy, but only ages at previous births.  
Wohlfahrt et al [70] also used the additional birth approach (Appendix 1).  
Assessing interaction by family history 
Study III assessed if the IRRs (risk pattern) around delivery were modified by family history 
of BC. This effect modification was included as a set of interaction terms between time-since-
pregnancy and family history in the weighted Poisson regression model. We specifically 
parameterised the risk pattern in women with family history and compared it to the pattern in 
women without a family history by testing the interaction terms in the model (Appendix 2). 
 
  35 
Figure 3.7 Comparisons using the additional birth approach, where the effect of the latest birth is 
compared to women without the additional birth and with the same reproductive history (number of 
previous births and age-at-first-birth). X indicates a birth. 
 
3.4.2 Analysis of tumour characteristics (study II, IV) 
In study II and study IV, the data was analysed by comparing TNM stage distributions 
(proportions) in different PABC windows using the Pearson Chi-squared test for categorical 
data. In study II, the test was applied to crude distributions, whereas in study IV the test was 
applied to age-standardized distributions.  
In study IV, we used age-standardisation (using the method of direct standardisation [157]) to 
adjust for confounding by age. The age distribution among women diagnosed during 
pregnancy and up to12 months post-delivery was used as the standard, and applied to the 
other time-since-pregnancy windows. The standardised tumour characteristic distribution in a 
given risk window was thus not the real observed distribution, but represented a situation 
where a hypothetical age distribution had been applied (similar to the situation with 
hypothetically age matched controls). Age was categorised into intervals 15-33, 34-36, 37-39 
and 40-44 years. 
Several other studies have utilised matching on age to make unbiased comparisons of PABC 
cases to non-PABC cases. However, matching is useful when only one risk window is 
compared. If one wishes to compare several time windows, then each risk windows requires 
its own aged-matched nulliparous comparison group.  
In study IV, the data was also analysed using multinomial and logistic regression models 
adjusted for age, period, education and family history of BC. The results were similar to those 
using the Pearson Chi-squared test on age-standardised distributions, indicating that the 
confounding from period, education and family history of BC was only minor. The easier-to-
interpret proportions are presented rather than the less intuitive relative risk ratios (RRR) and 
odds ratios (OR).  
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3.4.3 Analysis of mortality (study I, II, IV) 
In study I, flexible parametric survival models (FPM) were used to estimate HRs for 
mortality associated with PABC risk windows. FPMs are modelling the hazard rates across 
the underlying timescale (time-since-diagnosis) using a spline function [158, 159]. The model 
is extremely useful in that it captures smooth shapes of the hazard rate, and not step functions 
(as in Poisson regression). Interactions with time (non-proportional hazards) can be included 
to assess if the hazard rate is different over follow-up in different exposure groups. These 
time-varying effects are modelled as deviations from the baseline spline using additional 
spline terms. The results are typically presented graphically as smooth curves. The FPM is 
less useful in situations with few events at some part of the follow-up. 
In study II, Cox regression was used, since the short study period included very few deaths to 
study mortality. The Cox regression model does not assume any functional form of the 
baseline hazard and only estimates hazard ratios [155]. Hence, the Cox regression model does 
not require time-splitting of the data, and is particularly useful in situations with only one 
timescale of interest or in situations with sparse data.  
In study IV, Cox regression was used to estimate hazard ratios over the 10-year follow-up. 
We also assessed time-varying effects (non-proportional hazards) by use of FPMs. For time-
varying effects, the Cox model requires time-splitting, whereas the FPM does not.  
Models were adjusted for time-since-diagnosis, age and year at diagnosis, and educational 
level. The analyses in study IV were also adjusted for region of diagnosis. Since the 
maximum follow-up differed between studies, the overall HRs (from proportional hazards 
models) represent the average HRs for different lengths of follow-up since diagnosis.  
3.4.4 Confounders 
Age 
Since age is strongly associated with both timing of pregnancy and risk of breast cancer, age 
must be properly accounted for in any comparison of PABC to non-PABC (Table 3.4, Figure 
3.8). A comparison without adjustment for age will yield results skewed by younger PABC 
cases and older non-PABC cases.  
 
Table 3.4 Age at BC diagnosis by time since most recent pregnancy in women diagnosed with BC in 
Sweden 1992-2009 (from study IV) 
 BC 
Nulliparous 
PABC 
Pregnant or <2 yrs  
BC  
2-10 yrs  
BC 
>10 yrs  
Age at diagnosis, yrs N % N  % N  % N % 
15-24 28 2 5   1 3   0 0 0 
25-29 141 9 88 11 72   2 1 0 
30-34 276 17 277 36 509 14 49 1 
35-39 413 25 291 37 1309 36 532 16 
40-44 803 48 117 15 1705 47 2822 83 
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Figure 3.8 Age at BC diagnosis by time since most recent pregnancy in women diagnosed with BC in 
Sweden 1992-2009 (from study IV) 
 
Associations adjusted for age in broad intervals (e.g. 5 year) may still be influenced by 
residual confounding, since even within the 30-34 years interval the PABC women will be 
closer to age 30, while women with non-PABC are closer to 35 years. 
Women with non-PABC (which is a mix of nulliparous and parous >2yrs post-delivery) 
include a mix of age distributions: younger nulliparous women and older parous women. The 
nulliparous women alone therefore represent a younger comparison group than the combined 
non-PABC group (Figure 3.8). A weaker age gradient is also present in the PABC group: 
women diagnosed during 0-6 months post-delivery are the youngest, followed by women 
pregnant at diagnosis, and with the oldest women being diagnosed 12-24 months post-
delivery.  
Since age is more strongly associated with incidence (risk) than with prognosis, it represents 
a stronger confounder for risk than for prognosis (Figure 3.9). Hence, the models of mortality 
were only adjusted for age in 5 years categories. However, in study I the plotted hazards 
(mortality rates) were from a model unadjusted for age, and a comparison to the non-PABC 
groups is therefore not sufficiently adjusted (a comparison between curves of different PABC 
categories is however less confounded by age).  
Study II suffers from lack of control for age. The comparisons to the non-PABC group in the 
crude tables 1 and 2 were not adjusted for age, which are therefore biased. However, table 3 
was stratified on age and the Cox regression analysis was also adjusted for age. In study III, 
age was measured as a timescale. Age was split in 1-year categories and included as a 
smoothed (spline) function in the models, and the age adjustment was therefore thorough.  
Age is associated with TNM stage, Elston grade and ER/PR/Her2 status [11]. In study IV, the 
distributions were age-standardised to account for confounding by age. Because of the broad 
categorisation used in the age-standardisation, there may still remain some residual 
confounding in the estimated proportions. 
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Figure 3.9 Confounding by age for the association between (a) pregnancy-association and breast 
cancer risk, (b) PABC and TNM stage, and (c) PABC and mortality. 
 
Age is also associated with screening. Since women with non-PABC are more likely to be 
40-44 years at diagnosis, they may more often be detected at outreach mammography 
screening (which may also affect their TNM stage). In study IV, only 15% of women with 
PABC were 40-44 years (Table 3.4). Adjustment for age will account for some of the 
influence by screening, but not all, since pregnant and lactating women of eligible age for 
invitational mammography screening may be less likely to attend.  
Calendar period 
Calendar period of diagnosis is the second most important confounder in studies of PABC. 
Not only birth rates vary by calendar time, but also timing of childbearing, including trends of 
postponement of childbearing to higher age. Both incidence and survival of BC have changed 
over time, but these changes have been slow (Figure 1.1). In studies I and III, we used broad 
categories of period (10 year intervals) in the adjustments. Studies II and IV encompassed 
shorter study periods, and the mortality analyses in study IV were also adjusted for period in 
broad categories. 
Education 
The risk of pre-menopausal breast cancer is higher in women with high compared to low 
educational level [25]. Mortality following BC also differs by education [26]. Educational 
level is strongly associated with age at childbirth, where younger mothers tend to have a 
lower education [59]. However, the distribution of educational level is similar in mothers who 
give birth to their first child and mothers who give birth to their second or third child, i.e. 
parity and educational level is not associated [59].  
We obtained information on education from Census data and the Education Register, and 
defined highest attained education as the highest level recorded in these sources, starting with 
the most recent available data and searching backwards in time to an earlier source if the 
information was missing.  
Unmeasured confounding 
In studies based on observational data, unmeasured confounding, i.e. factors which we would 
have liked to control for in the analysis but for which data were unavailable, is a challenge. 
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Ideally, we would have liked to be able to control for breast feeding, use of oral 
contraceptives (OC) and factors related to fertility problems. Individual level information on 
breast feeding is not available for research purposes in any register at the NBHW. 
Prescriptions of OC (as a proxy for use) are recorded in the Prescribed Drug Register from 
2005. Conditions affecting fertility can be partly found in the MBR (for parous women) and 
in the Patient Register (for severe conditions requiring hospitalisation). However, it is very 
difficult to identify nulliparous women with fertility problems based on historical registers. 
The Q-IVF Quality Register includes couples who have undergone assisted reproductive 
treatments in Sweden since 2007. Nulliparous women represent a mix of women, e.g. those 
who are fertile but do not want children or those who are infertile and want children. These 
different groups of women may have different risks of BC. 
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4 RESULTS 
In summary, the main findings were (Figure 4.1): 
 Study I: Compared to women with non-PABC, the mortality in women with PABC 
was increased, with the most pronounced effects observed in women diagnosed 
during pregnancy and within 6 months of delivery. The poorer prognosis persisted up 
to 8 years after diagnosis.  
 Study II: Women with PABC had more advanced T and N stage at diagnosis, 
compared to women with non-PABC. Low power limited the possibility to draw 
conclusions regarding differences in mortality between women with PABC or non-
PABC before and after adjustment for TNM stage. 
 Study III: Compared to nulliparous women, the risk of BC was lower during 
pregnancy and increased 12-24 months following delivery. Among uniparous women, 
the BC risk was transiently increased 5-8 years post-delivery. Women with a family 
history of breast cancer had similar risk patterns as women without a family history.  
 Study IV: Women diagnosed with BC during pregnancy and within one year of 
delivery had more advanced TNM stage and more aggressive tumour characteristics 
(ER negative, PR negative, Her2 positive, high grade, triple-negative), compared to 
nulliparous women. The increased mortality in women with PABC was almost fully 
explained by tumour characteristics. Spread to lymph nodes was more common in 
women diagnosed between 2-10 years post-delivery, compared to nulliparous women. 
Following adjustment for tumour characteristics, a slightly elevated mortality was 
observed in women diagnosed 2-5 years after delivery. 
 
Figure 4.1 Overview of the main examined associations in study I, II, III and IV. 
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4.1 RISK PATTERNS (STUDY III) 
Study III investigated the incidence rate ratios (IRRs) of BC during pregnancy and up to ten 
years post-delivery in relation to family history of BC and parity. The main findings were: 
Risk pattern by time-since-pregnancy and parity (in women without family history) 
 The majority of women had no family history of BC (85.5%). 
 Compared to women without an additional birth, the risk for breast cancer was lower 
during pregnancy. No difference in risk was observed during the first year post-
delivery, while a small increase in risk was observed during the second year. This 
pattern was similar following first and second birth, but less pronounced following 
third birth (Figure 4.2). 
 Among uniparous women, there was a transient risk of breast cancer around 5-6 
years post-delivery. This transient risk was not present in biparous or triparous 
women (Figure 4.2). 
 
Figure 4.2 Breast cancer incidence rate ratios by time-since-pregnancy and family history of BC 
(Study III, Table 4) 
 
For uniparous women with a family history (black), the reference line represents nulliparous women 
with a family history. For uniparous women without a family history (grey), the reference line 
represents nulliparous women without a family history. Similarly, for biparous women, the reference 
group is uniparous women and for triparous women, the reference group is biparous women. This 
comparison (parameterisation) removes the main effects of family history and parity, and only displays 
the modifying effect from family history on time-since-pregnancy of each additional child. 
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Risk pattern by time-since-pregnancy and parity (in women with family history) 
 Around 14.5% of women had a family history of BC. 
 Regardless of parity, women with a family history of BC had similar IRRs during 
pregnancy and up to 2 years after delivery compared to women without a family 
history (Figure 4.2). 
 In uniparous women, a family history of BC did not influence the risk pattern up to 
10 years post-delivery compared to women without a family history (Figure 4.2).  
 In biparous women, there was some indication of elevated relative rates among 
women with a family history from 2 to 10 years post-delivery, but the estimates were 
not statistically different from women without a family history (Figure 4.2). 
 Contrary, in triparous women, there was some indication of reduced relative rates 
among women with a family history from 2 to 10 years post-delivery, compared to 
women without a family history (Figure 4.2). 
 Having a young onset family history (relative diagnosed with BC before age 50 
years) did not affect the risk pattern, with the possible exception during the second 
year post-delivery, where women with a young onset had a non-significantly higher 
relative rate (Figure 4.3). 
Figure 4.3 Breast cancer incidence rate ratios by time-since-pregnancy and family history with young 
or old age at onset in relative, all parities combined (study III, table 3)   
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4.2 TUMOUR CHARACTERISTICS (STUDY II, IV) 
TNM stage 
Study II and study IV examined the association between time-since-pregnancy and TNM 
stage at diagnosis. Study II included information from the SCR (2002-2009) based on clinical 
and pathologic TNM, while study IV included information on pathologic TNM available in 
the BCQR (1992-2009).  
The main findings on TNM stage at diagnosis were: 
 Women with PABC had more advanced TNM stage, mainly larger tumours (T) and 
more nodal involvement, compared to nulliparous women. There was no significant 
difference with regard to distant metastasis.  
 The largest tumours were diagnosed during pregnancy and within 6 months post-
delivery compared to nulliparous women (Figure 4.4). 
 Compared to nulliparous women, spread to lymph nodes was more common in 
women diagnosed during pregnancy and up to 2 years post-delivery, but also up to 10 
years post-delivery (Figure 4.4). 
 The association between PABC and TNM stage was mainly present in women aged 
35-44 years, but analyses were hampered by low power in the younger age groups 
(Figure 4.5). 
 
Figure 4.4 Age-standardised distributions of T and N stage by time-since-pregnancy (study IV, table 
2). Pearson Chi-squared test p-value <0.05 compared to distribution among nulliparous women is 
marked with *. 
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Figure 4.5 Distribution of TNM stage by PABC and age at diagnosis (study II, table 3). Pearson P-
values from Pearson Chi-squared tests comparing PABC to non-PABC. 
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ER, PR, Her2, grade and subtype 
Study IV assessed the distribution of ER, PR, Her2, grade and subtype by time-since-
pregnancy, and the main findings were: 
 Compared to nulliparous women, the proportions of ER and PR negative tumours 
were higher in women diagnosed during pregnancy and 0-6 months post-delivery. 
This pattern was less pronounced for women diagnosed within 6-12 and 12-24 
months post-delivery (Figure 4.6).  
 PR negativity was also more common in women diagnosed up to 5 years post-
delivery, compared to nulliparous women (Figure 4.6). 
 Her2 positivity was more common in women diagnosed 0-6 post-delivery, and to a 
lesser extent within 12-24 months and 5-10 years post-delivery, compared to 
nulliparous women (Figure 4.6). 
 Women with PABC more often had high grade tumours, compared to nulliparous 
women, but the differences were only significant in women diagnosed 6-24 months 
post-delivery (Figure 4.6). 
 Compared to nulliparous women, women diagnosed during pregnancy and within 12 
months of delivery were more likely to have triple-negative and non-luminal Her2 
positive tumours (Table 4.1). There was also some indication that women diagnosed 
12-24 months post-delivery were more likely to have Luminal B Her2 positive 
tumours (Table 4.1). 
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Figure 4.6 Age-standardised proportions of molecular markers (ER, PR, Her2) and grade by time-
since-pregnancy (study IV, table 3). Pearson Chi-squared test p-value <0.05 compared to distribution 
among nulliparous women is marked with *. 
 
  
Table 4.1 Age-standardised distributions (%) of BC subtype by timing of BC diagnosis in relation to 
time-since-pregnancy (study IV, table 4). 
 Nulli- 
parous 
Pregnant 0-6 mo 6-12 mo 12-24 mo 2-5 yr 5-10 yr 
 % % % % % % % 
Luminal A- or B-like Her2- 53 32 20 41 39 46 50 
Luminal B Her2+ 17 17 19 12 26 12 19 
Her2+ non-luminal 6 12 24 14 9 15 11 
Triple negative 23 33 35 34 24 25 16 
ER-/PR+ 2 5 2 0 2 2 4 
P-value (vs. nulliparous) (ref) 0.130 <0.001 0.040 0.056 <0.001 0.007 
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4.3 MORTALITY (STUDY I, II, IV) 
Studies I, II and IV investigated patterns of mortality following BC by time-since-pregnancy, 
and whether tumour characteristics could explain observed associations. The main findings 
were: 
 Women with PABC had a worse prognosis, compared to women with non-PABC (i.e. 
combined group of nulliparous and parous women >2 years of delivery) and to 
nulliparous women. Women diagnosed during the first 6 months post-delivery had the 
highest mortality (study I, IV) (Figure 4.7). Parity did not interact with the effect of 
PABC on mortality (study I). 
 An increased mortality was also observed in women diagnosed up to 5 years post-
delivery, albeit less pronounced (Figure 4.7, right). 
 The increased mortality in women with PABC was almost fully explained by adverse 
tumour characteristics (Figure 4.7, right). In women diagnosed 2-5 years, the hazard 
ratio was attenuated but remained significant after adjustment for tumour 
characteristics. These associations were not modified by age (study II, IV). 
 There was some indication of elevated mortality in women with node negative PABC 
tumours, compared to nulliparous women with node negative tumours (study II, IV). 
A similar association was observed for women with ER positive PABC tumours 
compared to nulliparous women with ER positive tumours (study IV). 
Figure 4.7 Hazard ratios with 95% confidence intervals by PABC and time-since-pregnancy with and 
without adjustment for tumour characteristics. (Study I, table 1; study II, table 4; study IV, table 5.) 
 
Confounders included age and year of diagnosis, educational level (and region, study IV only). 
Tumour characteristics included T stage, N stage (and ER/PR status, study IV only).  
Study I included 15-year mortality; study II 9-year mortality; study IV 10-year mortality. 
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Furthermore, study I and IV examined time-varying hazard ratios by time-since-diagnosis: 
 The increased mortality persisted up to 5-8 years years after diagnosis, with a peak 
around 2 years after diagnosis (Figure 4.8, left). Adjustment for tumour characteristics 
attenuated this pattern (Figure 4.8, right). 
 
 
Figure 4.8 Time-varying hazard ratio over time-since-diagnosis by PABC vs non-PABC, adjusted for 
confounders (left) and additionally for tumour characteristics (right) (study IV)  
 
Confounders included age and year of diagnosis, educational level and region. 
Tumour characteristics included T stage, N stage and ER/PR status. 
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5 DISCUSSION 
5.1 RISK BY TIME-SINCE-PREGNANCY AND FAMILY HISTORY (STUDY III) 
Parity and time-since-pregnancy 
An S-shaped risk pattern with a lower breast cancer risk during pregnancy followed by a 
higher risk within 2 years after delivery has been reported previously [58, 61-63]. This 
pattern may have several possible explanations, including: (1) a true lower risk during 
pregnancy associated with protection from biological changes, e.g. hormonal or 
immunological changes; (2) impaired detectability due to lower diagnostic sensitivity because 
of masking of tumours during pregnancy and lactation (leading to delayed diagnosis and 
lower observed incidence); (3) patients’ and doctor’s delays, malignancy-related signs and 
symptoms may be misinterpreted as normal pregnancy-associated changes in the breast tissue 
(leading to lower incidence during pregnancy and lactation); (4) lower screening intensity 
among pregnant and lactating women; (5) misclassified BC cases during pregnancy because 
of misclassification of women with spontaneous or elective abortions as non-PABC (would 
give lower incidence; this effect should be most pronounced during the first and second 
trimesters when abortions are more common); pre-malignancies may also affect fertility and 
the risk for spontaneous abortion leading to reverse causation (if the BC causes a lower 
fertility, the incidence during pregnancy would be lower); (6) a healthy mother effect, where 
fertility may be associated with lower prevalence of risk factors for BC (yielding a lower 
incidence for BC due to a selection of healthier women having children).  
The rebound effect during the second year after delivery could reflect a postponement of 
diagnosis due to (2)-(3) (leading to more advanced tumours at diagnosis). A higher risk 
during the second year after delivery may also reflect promoting effects of pregnancy-
associated hormonal, immunological or post-weaning involution changes. A latency period 
between exposure and detection is necessary for these effects to be plausible.  
The hormonal milieu and tissue changes during pregnancy, which could promote the growth 
of pre-malignant cells into detectable tumours, imply that the risk would be higher during 
pregnancy/lactation than what is observed. The masking of pregnancy would, however, 
counteract this effect and may prevent detection also of relatively large tumours. However, 
the issue of a reasonable latency period between exposure and effect is complex and must be 
taken into consideration; hormonal exposures during pregnancy may rather give rise to 
tumours detectable further away from delivery, and not during pregnancy.  
The risk pattern during pregnancy and within 2 years of delivery was similar for uniparous, 
biparous and triparous women, indicating that the mechanisms around delivery are not 
affected by the protection from previous pregnancies. This suggests that pregnancy-
associated factors rather than tissue factors drive the risk pattern close to pregnancy.  
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In line with the findings of study III, several authors found a peak in the incidence around 5-
10 years post-delivery [64-71], of which three studies also were based on Swedish data [65, 
66, 71].  
It has been suggested that the transient risk 5-10 years post-delivery is restricted to uniparous 
women [68, 69], which may be attributed to a tumour-initiating effect of pregnancy on tissue 
not previously exposed to the physiological and structural changes induced by childbearing. 
Parity is protective against breast cancer via several mechanisms [130], including: 
differentiation of epithelial cells, changes in hormone-responsiveness of the breast gland, 
reduction in the number of breast stem-cells, and altered levels of circulating hormones in 
parous women. The tissue in nulliparous women has not undergone these changes and may 
be particularly vulnerable to exposures from a first pregnancy, especially at older ages. Since 
the aim of study III was to assess the impact of family history, we did not have power to also 
include an interaction with age among uniparous women. 
Family history and time-since-pregnancy 
The hypothesis that women with a family history of breast cancer, who have been suggested 
to be more likely to harbour pre-malignant breast cells at a young age, would be more 
susceptible to the tumour-promoting effects of pregnancy was not supported by the findings 
in study III. In contrast to the findings of Hou et al [87], we found that having a family 
history of BC did not alter the risk pattern during pregnancy or within 2 years of delivery. 
Hence the risk pattern around pregnancy appears to be unrelated to familial factors. This 
finding was consistent over different parities, and it does not support the tumour promoting 
hypothesis, but rather the detection delay hypothesis, which would affect risk independently 
of family history.  
The finding of no effect of family history on the transient risk of BC 5-10 years after delivery 
was in line with results from some previous studies [85, 86] and is less enigmatic, since a 
promoting effect of pregnancy in women with a family history would be expected to be 
manifested closer to delivery.  
Two publications have reported increased risks following childbearing in women with a 
family history (Wohlfahrt et al [86] in uniparous only; Albrektsen et al [84] overall, difficult 
to assess the models by parity). Study III showed slightly elevated, though non-significant, 
risks following the second birth in women with family history compared to no family history. 
This finding indicates that having a second child would confer a higher risk in women with a 
family history of breast cancer. In light of the hypothesis regarding protection from parity, 
this does not make sense however. If there was a modifying effect of family history following 
the second birth, then there should be a similar, or stronger, modifying effect following the 
first birth. 
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Methodological considerations 
Assessing three-way interactions 
Low power was a challenge when assessing the modifying effect of family history on the risk 
pattern around pregnancy. Despite the relatively large number of women with BC, the 
numbers reduced substantially when divided by time-since-pregnancy intervals, parity and 
family history. This limited the possibility to draw conclusions on the three-way interaction 
between time-since-pregnancy, parity and family history. The comparison of women with 
young and old onset family history was therefore assessed for all parities combined, although 
it precluded evaluation of the transient risk among uniparous women only by young and old 
onset family history status. 
Parameterisations of effects 
The studies examining family history as a modifier of the risk pattern around delivery were 
conducted in similar Nordic settings [84-86, 160], with the exception of Hou el al [87] which 
represents a non-Nordic population in a more recent period (Table 5.1). 
A challenge when comparing these studies [84-87, 160] is that different comparison groups 
were used to assess the interaction between family history and time-since-pregnancy (see 
Appendix 1). We used the same method as in Wohlfahrt et al [86] which compares women 
with a birth to women not having that additional birth, i.e. uniparous women to nulliparous, 
biparous to uniparous and so on. This approach captures the effect of having an additional 
child in women of similar reproductive history, i.e. the effect of the most recent pregnancy 
everything else held constant. Since parity has an independent effect on breast cancer risk, 
this is a straightforward way to control for parity while assessing the impact of a new birth 
and by family history. Albrektsen et al [84] and Hemminki et al [85] used other comparison 
groups (Albrektsen et al: nulliparous without family history; Hemminki et al: all parous 
women with/without family history), and thus the effects are not exactly comparable. While 
Albrektsen et al could not distinguish the overall effect of family history (which has a RR of 
around 2-3) from the modifying effect of family history, Hemminki et al compared the risk in 
each time window to the average risk of women with the same parity. Hou et al [87] assessed 
the effect of family history in categories of time-since-birth, whereas the other studies 
examined the effect of time-since-birth in categories of family history. Since interactions are 
symmetric, the conclusions from Hou et al should, in theory, be similar to the other studies 
although effect estimates will differ.  
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Table 5.1 Key references on family history of BC and risk by time-since-pregnancy. 
Author 
Year 
Journal 
Country 
Period 
Age 
BC with  
family history 
BC without 
family history 
Definition of  
family history 
Risk  
Windows 
Johansson et al 
(2015)  
Br Ca Res Trt 
Sweden  
1963-2009  
15-44y 
0-5y:   N=257        
5-10y: N=370   
0-5y:   N=2587      
5-10y: N=3072    
mother, sister 
(by </>50yrs) 
Pregn, 0-1, 
1-2, 2-4, 4-
6, 6-8, 8-10, 
10+ yrs 
postpartum 
Hou et al  
(2013) 
Annals Epi 
Nigeria  
1998-2011  
21-50y 
0-2y:  N=9        
3-5y:   N=8 
0-2y:  N=143        
3-5y:  N=136 
unclear Pregn-2yr,  
2-5 yrs 
postpartum 
Hemminki et al 
(2008) 
Br Ca Res Trt 
Sweden  
1958-2004  
13-72y 
0-5y:   N=170        
5-10y: N=368 
0-5y:   N=1929       
5-10y: N=3624 
mother, sister, 
daughter 
0-46 yrs 
postpartum. 
5yr intervals 
Albrektsen et al 
(2006) 
IJC 
Norway  
1955-1999  
20-78y 
0-5y:   N=80        
5-10y: N=94 
0-5y:   N=603       
5-10y: N=793 
mother, sister 
(by </>50yrs) 
0-30 yrs 
postpartum. 
Spline 
Wohlfahrt et al 
(2002) 
CCC 
Denmark 
1968-1990 
<40y 
0-5y:   N=106      
5-10y: N=143 
0-5y:   N=713       
5-10y: N=1345 
mother 0-10+ yrs   
5yr intervals 
 
Another issue is that time-since-pregnancy is not defined for nulliparous women. This is a 
methodological problem present in many epidemiological exposures that include duration 
[161]. We, and others [70, 84, 86], have tried to address this problem by using different 
parameterisations, such as the additional-birth approach. Nulliparous women will follow 
other timescales, e.g. age and calendar time, and can be compared to parous women who also 
follow these timescales in addition to time-since-pregnancy. The comparison to nulliparous 
women of the same age and period means that the age effect is adjusted for in the time-since-
pregnancy estimates. Without the age adjustment, the rates would increase by time-since-
pregnancy simply because women age as time passes. 
The focus of study III was to assess effects by time-since-pregnancy while adjusting for age. 
Adjustment for age-at-first-birth was only possible among biparous and triparous women, 
since age, time-since-birth and age-at-first-birth are collinear in uniparous women. 
Adjustment for age-at-first-birth ensured that women had similar reproductive history and 
time between first and later births. 
Effects of age 
The adjustment for age was thorough in study III, via fine time-splitting on age (in 1-year 
intervals) and including the age effect as a spline in the Poisson model. Residual confounding 
was therefore small. 
A limitation of study III was that interactions with age were not assessed. This was due to 
lack of power, since we primarily assessed the three-way interaction between time-since-
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pregnancy, parity and family history. However, the effect of time-since-pregnancy in 
uniparous women was primarily observed among women aged 35-44 years at diagnosis (data 
not shown in paper). This is no surprise since most data (BC cases) were in this age group. 
Furthermore, when assessing pregnancy effects in the oldest age group (40-44 years), there 
was a limitation in the time of follow-up, since the cohort was censored at age 44 (to avoid 
perimenopausal BC). The risks at >5 years post-delivery were therefore not examined in 
women who had children after age 40.  
Selection bias in the nulliparous comparison group over age could also occur. Over the life-
course, women start out as nulliparous, but by age 45 those that remain nulliparous are a 
selected group, consisting of a mix of women who does not wish to have children and women 
with fertility problems. Similarly, uniparous, biparous and triparous women as groups change 
across age, and include both women who have attained their wished parity, and those who 
have not. Women with fertility problems may have a different risk pattern for BC, and thus 
the average risk in the comparison group may change across ages.  
Misclassification 
By use of information available in population-based registers we were able to identify 
virtually all women diagnosed with BC between ages 15 to 45 years during the period under 
study. Pregnancies were defined as “liveborn children”, and thus pregnancies ending in 
abortions or miscarriages were not included. This under-ascertainment (misclassification) of 
exposure was likely to be similar for women with or without a family history of BC. Family 
history of breast cancer was assessed using information in the MGR and SCR. Because of the 
start years of the registers, some mothers (and a few sisters) with early breast cancer were not 
identifiable. However, the estimated proportion (14.5%) of breast cancer cases with a family 
history of BC was similar to estimates in other populations [13]. 
5.2 TUMOUR CHARACTERISTICS BY TIME-SINCE-PREGNANCY (STUDY II 
AND IV) 
TNM stage – size and spread 
The finding that women diagnosed with BC during pregnancy and up to one year post-
delivery had larger tumours and more regional spread to the lymph nodes (study II, IV) is in 
line with results from previous studies [93, 95, 96, 98-101, 106], including the two largest 
studies to date [95, 99].  
Several mechanisms could explain these findings. (1) The tumours may be more aggressive, 
due to tumour growth promoting changes in the breast tissue during pregnancy and lactation. 
(2) The tumours may be larger due to diagnostic delays either because of (a) impaired 
detectability due to masking in dense breast tissue (mainly of small tumours, but also of 
larger ones), (b) absence or misinterpretation of signs and symptoms by patient or doctor, or 
(c) lower screening intensity among pregnant and lactating women. 
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Lower sensitivity of diagnostic procedures during pregnancy and lactation has been 
suggested. However, such a delay would be counteracted by that pregnant women with 
symptoms are prioritised and receive continuous attention as part of maternal follow-up in the 
health care system.  
Mammography screening impacts the distribution of TNM stage at diagnosis since screen-
detected tumours are found earlier and thus are smaller. About 40% of breast cancers in 
women of screening age in Sweden are detected via outreach mammography screening and 
the remaining 60% are detected because of symptoms [125]. Less screening among women 
with PABC can partly explain the observed TNM stage differences compared to women with 
non-PABC. Firstly, while only 15% of all women with PABC were 40-44 years at diagnosis, 
more than 60% of non-PABC patients were diagnosed in that age interval, and hence they are 
more likely to have been diagnosed by screening. Adjustment for age would control for these 
differences, although residual confounding may be present. Secondly, pregnant and lactating 
women above 40 years of age are less likely to attend mammography screening. Such bias 
due to mode of detection cannot be excluded even in an age-adjusted comparison within the 
age group 40-44 years. 
Women aged 35-44 years at diagnosis of PABC had more advanced tumours than women 
with non-PABC, but the effect was less pronounced and non-significant in women diagnosed 
below 35 years (study II). Two previous studies which assessed PABC in women below 35 
years found more advanced T and N stage disease among PABC compared to non-PABC 
[100, 105].  
Similar to results reported in earlier studies [70, 102, 112, 113], we found that tumours 
diagnosed between 2 and 10 years after delivery had more regional spread compared to 
nulliparous women, (study IV). Contrary to our finding of no difference in tumour size, two 
of these studies [70, 112] also found more advanced T stage in tumour diagnosed 2-5 years 
post-delivery. Three studies found no advanced T or N stage beyond 2 years [93, 103, 108].  
ER, PR, Her2, grade and subtype 
In line with some [95, 96, 98-100, 110], but not all previous studies [106], results from study 
IV showed that tumours diagnosed during pregnancy and within one year of delivery were 
more often ER and PR negative, in particular 0-6 months post-delivery. These tumours were 
also more often of grade III, corroborating findings from earlier studies [94-96, 98, 114]. 
Further, these tumours were more likely to be triple-negative and non-luminal Her2 positive, 
a finding which has been reported previously in pregnant women [95] and in women 
diagnosed 0-2 years after delivery [107, 108]. These associations were present, albeit less 
pronounced, during the second year post-delivery.  
The finding of increased proportions of hormone receptor negative tumours among women 
with PABC must be viewed in the light of the findings on TNM stage and the risk pattern 
around delivery. Since different subtypes of BC have different stage distribution at diagnosis 
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[162], which is reasonable given the differences in aggressiveness between subtypes, it is 
difficult to disentangle the effect of diagnostic delays merely by assessing subtypes. An 
outstanding question is: If a delay mechanism is present, what are the characteristics of the 
“missing breast cancer tumours” during pregnancy and lactation? 
The increased proportions of ER and PR negative tumours around delivery do not support the 
hypothesis that the hormonal exposures during pregnancy promote hormone sensitive 
tumours. Instead, the opposite was observed. In combination with the lower risk during 
pregnancy, the finding could be interpreted as a suppression of ER and PR positive subtypes 
during the pregnancy time window. It is also possible that more aggressive (ER/PR negative), 
larger tumours are diagnosed during pregnancy and lactation because of diagnostic delays or 
masking of less aggressive (ER/PR positive), smaller tumours, i.e. a detection effect resulting 
in differences in stage and tumour biology at diagnosis. Such a delay should give rise to a 
higher proportion of large, aggressive tumours during pregnancy and lactation and a higher 
proportion of large, less aggressive tumours later (Figure 5.1). This is partly supported by the 
findings of TNM stage and tumour biology in women diagnosed 6-12 and 12-24 months 
post-delivery. Also, the finding in study III of no increased risk 0-12 months after delivery 
may be confounded by a too long window, given that Andersson et al [58] found a lower risk 
0-6 months and an increased risk 6-12 months post-delivery. The lower risk 0-6 months post-
delivery is interesting given that the most adverse tumour characteristics were observed 0-6 
months post-delivery.  
Figure 5.1 Schematic picture of possible effects of diagnostic delays during pregnancy and lactation 
on TNM stage and tumour biology at diagnosis, under the assumption of same underlying risk for BC 
before and after delivery. Small, less aggressive tumours during pregnancy (and lactation) would be 
delayed and may have increased in size and spread due to the delay. 
 
It has been suggested that tumours diagnosed during pregnancy and lactation have different 
biological characteristics compared to tumours detected prior to or after childbearing [132]. 
Thus, different mechanisms may drive breast cancer risk and detection close to or further 
away from delivery, e.g. tumours detected closer to delivery may originate from a tumour-
promoting mechanism, while tumours detected 5-10 years post-delivery may be initiated by 
pregnancy. 
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While the observed associations were strongest close to delivery, there were also findings of 
interest for tumours diagnosed between 2 and 10 years post-delivery. In line with results from 
earlier studies [102, 107-109, 112-114], tumours diagnosed during this time window were 
similar to tumours in nulliparous women with respect to ER status. However, we also found a 
slightly higher proportion of PR negative tumours, which only has been reported in one 
previous study [114]. Similar to some earlier studies [94, 113, 114], but not all [70, 102, 112], 
we found no difference in grade beyond 2 years post-delivery. 
It is of interest to relate these findings to the transient risk occurring around 5-10 years post-
delivery, mainly among uniparous women. Although the risk is increased, the tumours appear 
to have similar molecular features as tumours diagnosed in nulliparous women of the same 
age. A limitation, however, was that study IV did not assess tumour characteristics in 
uniparous women separately. 
Methodological considerations 
Age adjustment 
When interpreting the results from study II, age is an important confounder which was not 
adequately adjusted for (except for Table 3 which was stratified on age) (Figure 5.2a). The 
majority of non-PABC patients in study II were 40-44 years, an age group for which 
mammography screening was available for part of the study period (2002-2009) [47]. Since 
mammography screening is associated with less advanced TNM, the non-PABC group is not 
comparable to the younger (mainly unscreened) PABC group. However, women within the 
PABC group are similar in age and the comparisons of different PABC windows are less 
biased.  
In study IV, we undertook several steps to ensure proper age-adjustment of the comparisons 
over time-since-pregnancy. Several earlier studies have utilised age-matching. This imposes 
an age-structure on the nulliparous group that is different from the age structure of 
nulliparous cases in the population. Since the aim of study IV was to compare several time-
windows post-delivery to nulliparous women, a matching strategy would have been difficult, 
since each time-window would require a separate set of age-matched nulliparous women. As 
an alternative, we utilised age-standardisation, which applies the same age-structure (the 
standard age distribution) onto all time-windows, providing a valid comparison over time-
since-pregnancy intervals. Age standardisation is also statistically more efficient since it 
utilises all the data (via weighting), rather than a matched subset of nulliparous women. A 
limitation of the age-standardisation was that age categories used were broad (15-33, 34-36, 
37-39, 40-44 years), and did not preclude residual confounding. 
The age-standardisation showed that confounding by age did have a considerable impact on 
the distributions of tumour characteristics in nulliparous women and women diagnosed more 
than 5 years post-delivery. This observation has implications for the interpretation of other 
studies which did not adjust for age [95, 97]. It is noteworthy that some differences in age 
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also occurred within the PABC window; women diagnosed during the first year post-delivery 
were somewhat younger compared to women diagnosed during pregnancy and the second 
year post-delivery.  
Other confounders 
Our results (study II, IV) were not adjusted for calendar period. Some earlier studies have 
matched on both age and period [96, 98, 104, 106, 119]. The two largest studies to date on 
BC diagnosed during pregnancy have either matched on age only [99] or were unmatched 
[95]. However, compared to age, period is likely to be a less strong confounder of the 
association between timing of diagnosis and delivery, and tumour characteristics (Figure 
5.2b). If the availability or assessment of tumour markers have changed over time, then 
period may introduce confounding, particularly since PABCs are more common in more 
recent years. To assess the effect of confounding by period, we also modelled the proportions 
using logistic and multinomial regression (data not shown in paper IV) and the results 
showed only minor effects of period confounding. We decided to standardise on age only, 
since standardising on both age and period would have introduced additional randomness due 
to sparse data (more cells of combinations of age and period).  
Similarly, confounding by region was assessed in adjusted regression models with minor 
impact on the results (study IV).  
 
Figure 5.2 Potential confounding by age (a), period and region (b) of the association between PABC 
(time-since-pregnancy) and tumour characteristics. 
 
 
Measurement error and misclassification 
Clinical (pre-surgery) assessment of TNM stage in pregnant and lactating women is less 
precise because of pregnancy-associated changes of the breast tissue [49-51]. Study II used 
TNM information from the SCR, which represents a mixture of clinical and pathologic TNM. 
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Hence, the results from study II are not directly comparable to study IV, which was based 
exclusively on pathologic (post-surgery) TNM assessment.  
Compared to the initial assessment of tumour size at detection, women who receive 
neoadjuvant treatment will have a less advanced pathologic TNM stage. In study IV, only 
11% of the women received neoadjuvant treatment. Hence, differences in neoadjuvant 
treatment can only explain a small part of the difference in TNM stage between PABC and 
non-PABC, which was also corroborated by a sensitivity analysis.  
Stage in the SCR (study II) was included from 2002 with an increase of completeness from 
59% in 2002 to 96% in 2009. Contrary in study IV, TNM stage information was available for 
years 1992-2009 in the BCQR, but the West region was excluded from the T stage 
component (due to an unexplained skewed distribution of tumour size) and the South region 
was excluded from the M stage component (due to completely missing information on 
metastasis). Hence, 57% of women had a measurement of the combined pathologic TNM 
stage information representing four regions, and there were only minor differences in 
completeness by year of diagnosis and PABC status (time-since-pregnancy).  
Information on grade was available in all regions, but varied by inclusion year in the BCQR, 
with the earliest regions including information from 1995, while the latest regions included 
information since 2008. Data on ER and PR status were less complete (around 25-30% 
missing) because two regions (South and North) did not include these variables in the BCQR 
until early 2000s. Data on Her2 status were even less complete (around 75% of women had 
missing information) because Her2 was not included in any region in the BCQR until the 
early 2000s. As a consequence, information on BC tumour subtype, which was based on ER, 
PR and Her2 status, was also suffering from incomplete data. However, the missing pattern 
was similar in women with PABC and non-PABC (70% and 76% missing, respectively), and 
the distribution of ER/PR was similar for women with or without information on Her2. 
In conclusion, the incomplete information on tumour characteristics in study IV was mainly 
due to administrative missing, i.e. by differences in inclusions years to the BCQR in the 
different regions, and was therefore likely to not be associated with PABC status. 
Some studies have indicated that the essays used for ER and PR determination are not as 
exact for pregnant as non-pregnant patients with breast cancer [163]. However, data is limited 
and further research is needed to improve the understanding of how pregnancy and lactation 
may affect the quality of tumour marker measurements. 
5.3 MORTALITY BY TIME-SINCE-PREGNANCY (STUDY I, II AND IV) 
Mortality by time-since-pregnancy 
In line with most [95, 99, 101, 103, 104, 106, 117, 122, 123], but not all previous studies [98, 
100], we found that women diagnosed during pregnancy and within one year of delivery had 
a poorer prognosis (study I, II, IV) compared to non-PABC and nulliparous women (highest 
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mortality was observed 0-6 months post-delivery). A comprehensive meta-analysis including 
30 studies, in which our study was included (study I), concluded that PABC is associated 
with a higher mortality compared to non-PABC (pooled HR=1.44, 95% CI 1.27-1.63) [122]. 
Stensheim 2009 et al [117] found a higher mortality among women diagnosed 0-6 months 
post-delivery, but not among women diagnosed during pregnancy. 
Possible explanations include: (1) More aggressive tumours with poor prognostic markers 
(e.g. ER, PR negativity); (2) More advanced tumours at diagnosis reflecting aggressive 
tumours or diagnostic delays attributed to (a) masking due to pregnancy-associated changes 
in the breast tissue, (b) lower sensitivity of diagnostic procedures, or (c) lower screening 
attendance; (3) postponement of or less intensive treatment. However, recent data indicate 
that women with PABC have shorter waiting times to treatment compared to women with 
non-PABC, indicating that pregnant BC patients are prioritised by the healthcare system 
[164].  
We found no effect modification by previous parity on the association between PABC and 
prognosis. This is in line with the results from study III, which concluded that the risk pattern 
within 2 years of delivery was similar regardless of number of childbirths; while parity only 
affected the transient risk. 
Compared to nulliparous women, a significantly worse prognosis was also observed in 
women diagnosed 2-5 years post-delivery (study IV), corroborating results of earlier studies 
[103, 112, 113, 115, 116, 121, 124] of which two were based on Swedish data [115, 116], but 
not all [123]. These observations may be explained by more advanced tumours (in particular 
N stage) at diagnosis compared to nulliparous women. However, it is unlikely that women 
diagnosed with BC 2-5 years post-delivery should be affected by diagnostic delays, nor that 
they should attend screening to a lesser extent than nulliparous women. Further, there should 
not be any difference in treatment intensity. 
Mortality by time-since-diagnosis 
Following adjustment for confounders, we observed an increased mortality that persisted up 
to 8 years after diagnosis compared to non-PABC (study I and IV). A Norwegian study [121] 
found that the hazard ratio was elevated the first five years post-diagnosis, but attenuated and 
non-significant beyond 5 years. Several other studies have reported Kaplan-Meier curves 
indicating an increased mortality shortly following diagnosis, but few of the studies have 
reported age-adjusted estimates (such as age-matched K-M curves) [96, 100, 106]. Taken 
together, the effect of pregnancy and lactation on prognosis appears to be transient, indicating 
that the poor outcome may be related to aggressive, fast growing tumours.   
Mortality adjusted for tumour characteristics 
The observed higher mortality in women diagnosed with PABC was almost fully explained 
by adverse tumour characteristics (study IV). Thus, although women present with more 
advanced and aggressive tumours during pregnancy and within one year of delivery, the 
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prognosis is similar to that of nulliparous women with the same extent and severity of disease 
at diagnosis. This finding could reflect not only delays in diagnosis, but possibly also a more 
optimal treatment and rapid management of pregnant and lactating women, which would 
counteract negative effects of pregnancy on survival. To assess this hypothesis further, 
adjustment for treatment would be required (something which was not possible based on 
available data) (Figure 5.3).  
Figure 5.3 Possible patterns of associations between PABC, tumour characteristics, treatment and 
prognosis. 
 
 
Several studies have found evidence of poorer prognosis in women with PABC even after 
adjustment for tumour characteristics [99, 101, 104, 106, 107, 112, 113, 117, 123, 165], 
whereas a few did not [95, 98, 121].  
The two largest studies to date included 797 women with BC diagnosed during pregnancy 
(n=187) and up to one year of delivery (n=610) [99], and 311 women with BC diagnosed 
during pregnancy [95], respectively. While Rodriguez et al [99] utilised an age-and-period-
matched design within a population-based cancer register, the study by Amant et al [95] was 
based on a multi-center design with cases identified from 8 different countries and a control 
population from one country only. The analyses on tumour characteristics were not age 
matched, but the mortality analyses were adjusted for age. Despite the lack of control for age, 
the results from Amant et al are broadly in line with our findings (study IV). Some older, 
methodologically well-designed studies also require mentioning [101, 104]. Apart from these 
studies, there are numerous reports based on smaller, often single-institution hospital-based 
materials. Because of low power and selection issues, results have been inconsistent and 
preclude firm conclusions. 
Because of issues related to optimal treatment and safety, pregnant women with breast cancer 
have been given special attention in the literature. However, it is of note that not only the 
pregnancy period, but also the 0-12 months post-delivery period represents an important 
window with evidence of aggressive disease and poorer outcomes.  
The finding of a higher mortality in women with ER/PR positive or lymph node negative 
PABC tumours warrants further research. Similar findings have been reported in one small 
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previous study [107], but not in Amant et al [95]. Generally, hormone receptor positive and 
node negative tumours have a good prognosis, but our results indicate that they may confer a 
poorer prognosis if diagnosed near a pregnancy. 
It is also of interest to compare breast cancer to other cancer sites, since methods for detection 
and underlying biological mechanisms during childbearing may be similar or different. The 
incidence and prognosis following pregnancy-associated cancer appear to differ between 
cancer sites [58, 62, 117]. The three most common sites of pregnancy-associated cancer are 
breast, malignant melanoma and cervical cancer. Of these, pregnancy-associated breast 
cancer have the worse prognosis, while results from most studies to date suggest that 
melanoma has no difference in prognosis by pregnancy-association [166].  
The mortality was increased in women diagnosed 2-5 years after delivery (study IV), also 
after adjustment for tumour characteristics, although the point estimate was attenuated. This 
group warrants further research. It is very rare to include this not-so-near-pregnancy window 
in studies of PABC. The literature can be divided into studies on PABC (pregnancy and up to 
1 or 2 years) [95, 96, 98-100, 104-106, 117] and studies on BC diagnosed up to 5 or 10 years 
after delivery [70, 107, 112-114, 121, 123, 124, 165]. Only a few studies to date have 
examined both time-windows [93, 94, 97, 102, 103].  
Methodological considerations 
Confounding 
The survival analyses of study I, II and IV were adjusted for age in five-year categories. This 
categorisation should yield sufficient age-adjustment, given that the association between age 
and mortality is weaker than the association between age and incidence (study III). 
The results from study I, II and IV were adjusted for calendar year of diagnosis. Study I was 
based on older data from 1963-2002, which could be affected by changes over time in 
incidence, classifications, laboratory methods, treatment and mortality. Studies II and IV 
included information from more recent calendar periods, and therefore reflect a more recent 
clinical situation. Crude survival was also lower in study I compared to study II and IV. 
However, the relative effects of PABC were similar across the three studies. The results were 
also adjusted for educational level (study I and IV) and region (study IV). 
The adjustments for tumour characteristics in study IV may suffer from incomplete data on 
some tumour characteristics (though T/N stage and ER/PR status with at least 70% available 
data were included). This could potentially bias the results, if the incompleteness is 
differential between PABC and non-PABC. However, the missing patterns were similar in 
women with PABC and non-PABC, indicating non-differential missing in the BCQR 
register. 
There could be residual confounding by T and N stage even following adjustment, as the T 
and N stages were categorised broadly. Within levels of T and N stage there could still be a 
  63 
gradient of PABC being associated with more advanced tumours, and this could partly 
explain the remaining effects seen in some categories also after adjustment. However, a 
sensitivity analysis showed that when adjusting for T and N stage in a continuous manner, the 
effect estimates remained essentially unchanged. 
Follow-up for death  
Study II had limited power to assess mortality, since the follow-up for death ranged from 0-9 
years after diagnosis and was likely too short. Since the largest differences in mortality 
between PABC and non-PABC were observed within 5 years of diagnosis (studies I, IV), a 
follow-up of 5 years should suffice to draw conclusions on prognosis. Studies I and IV 
included 15 and 10 years of follow-up for death, respectively, and the majority patients could 
be followed for at least 5 years.  
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6 CONCLUSIONS AND IMPLICATIONS 
Risk pattern 
 The risk of breast cancer was lower than expected during pregnancy and modestly 
elevated around 12-24 months post-delivery. An additional peak in risk was observed 
around 5-8 years post-delivery (mainly among uniparous women). 
 Family history of breast cancer did not influence the breast cancer risk pattern during 
pregnancy and up to ten years post-delivery.  
 Possible exceptions from the overall finding of no modifying effect of family history 
were in women with a young onset family history the second year post-delivery and 
in biparous women 2-10 years post-delivery, where point estimates were non-
significantly elevated.  
Tumour characteristics 
 Women with breast cancer diagnosed during or within one year of pregnancy were 
more likely to present with advanced T and N stage, ER/PR negative (triple-negative 
and non-luminal Her2 positive), high grade tumours, compared to nulliparous women. 
 Tumours diagnosed during the first six months post-delivery exhibited the most 
aggressive tumour characteristics.  
 Tumours diagnosed 12-24 months post-delivery were more often PR negative, Her2 
positive, of high grade and advanced N stage, compared to nulliparous women. 
 Tumours diagnosed 2-5 years post-delivery were more often PR negative and of 
advanced N stage, compared to nulliparous women. 
Prognosis 
 Women with PABC had a poorer prognosis compared to women with non-PABC, 
when comparing women with same age, diagnostic period and level of education. 
 The highest mortality was found among women diagnosed during pregnancy and 
within the first year post-delivery, in particular women diagnosed 0-6 months post-
delivery.  
 Tumour characteristics explained most of the difference in mortality between PABC 
and non-PABC. 
 Women diagnosed 2-5 years after delivery also exhibited an elevated mortality, 
compared to nulliparous women, which remained significant after adjustment for 
tumour characteristics. 
Methods 
 A register-based approach is useful when studying rare events such as PABC. Still, 
some of the analyses included in this thesis were hampered by low power. 
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 The case-cohort design was a powerful study design for studying incidence in 
situations with multiple timescales, such as time-since-birth, age and calendar period. 
 Studies of pregnancy-associated breast cancer must account for the strong 
confounding by age.  
 The choice of comparison group (non-PABC or nulliparous) is important to consider 
since breast cancer risk, tumour characteristics and prognosis may differ between 
nulliparous and parous women. 
Despite the low risk of BC during pregnancy, the tumours which are diagnosed have adverse 
tumour characteristics leading to a poor prognosis (Figure 6.1). It is striking that the majority 
of these tumours are triple-negative or non-luminal Her2 positive, and not hormone 
responsive. Possible mechanisms include a suppression of luminal tumours and diagnostic 
delays during pregnancy.  
The first six months after delivery represents a time window with low risk, but with the most 
aggressive tumours (triple-negative and non-luminal Her2 positive) and the poorest 
prognosis. After adjustment for tumour characteristics, these patients have the same prognosis 
as women with non-PABC, suggesting that once these patients are given treatment 
corresponding to their characteristics, they have no survival disadvantage compared to other 
patients. To verify this conclusion, future studies examining treatment patterns in this patient 
group would be of importance. 
During the second year after delivery, the effects of pregnancy are less strong, although 
women still present with more advanced tumour and with slightly adverse tumour 
characteristics, compared to nulliparous women. Both the risk and mortality is however 
slightly increased. If pregnancy and lactation represents a window of delayed diagnosis, we 
would expect to see an increase in number of breast cancers of advanced TNM stage in this 
time window (shortly after lactation). After adjustment for tumour characteristics, these 
patients have the same prognosis as women with non-PABC, a finding which supports the 
hypothesis of a delayed diagnosis.  
A transient risk for breast cancer is present between 5 and 8 years post-delivery, mainly 
following the first birth. However, the tumours that are diagnosed in this time window are 
very similar to tumours diagnosed in nulliparous women of the same age, with the possible 
exception of slightly higher proportions of advanced N stage and PR negative tumours. There 
is also a moderately increased mortality in women diagnosed 2-5 years post-delivery, 
compared to nulliparous women, which is only partly explained by more adverse tumour 
characteristics.  
It is reassuring that women with a family history of breast cancer carry no increased risk for 
PABC. Provided that women with PABC receive the same level of treatment as non-PABC 
with similar tumour characteristics, these studies show that they have as good survival as any 
woman in their age group. 
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Although pregnant patients are a special group, it is also important to highlight the group of 
patients diagnosed shortly after a delivery, especially those diagnosed around 2-5 years post-
delivery, which potentially have a worse survival even after taking tumour factors into 
account.  
Figure 6.1 Schematic figure of overall risk pattern, tumour characteristics and mortality (unadjusted 
for tumour characteristics) by time-since-pregnancy in comparison to tumours diagnosed in 
nulliparous women of same age. 
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7 FUTURE PERSPECTIVES 
Although the studies included in this thesis are some of the largest studies to date on PABC, 
several comparisons were hampered by low power, including the assessment of tumour 
characteristics in women with PABC. Also, the ability to assess finer time windows was 
limited by the small number of cases. Hence, in order to further improve the understanding of 
PABC, international collaborations and pooling of data are essential. One existing project is 
led by the German Breast Group [95], which identifies and recruits pregnant women 
diagnosed with BC in several European countries and institutions. There is however room for 
register-based collaborations across countries, in particular in the Nordic countries where 
birth registers and cancer registers can be linked on individual level using PINs.  
Larger datasets are also needed for future evaluation of maternal and foetal risks following 
treatment of pregnant or recently pregnant patients. The introduction of new treatments and 
revised guidelines for pregnant patients should be evaluated across time and populations in 
epidemiological studies, as pregnant women are typically not eligible for randomised studies. 
However, detailed information on management are not included in the national registers, so 
additional data sources, such as clinical databases or information from medical records, will 
most likely be required. This, in turn, requires appropriate study designs to optimise the use 
of available data. In addition, outstanding questions regarding delays in symptoms, diagnosis 
and treatment in women with PABC require detailed information not available in national 
registers, e.g. medical records.  
However, large historic datasets with limited resolution, such as the national cancer registers, 
will remain an important data source for evaluating time trends of PABC incidence and 
survival. One outstanding question is to what extent the increase in PABC incidence over 
calendar time is related to shifts in maternal age over time. It is also of interest to make 
projections of future changes in breast cancer incidence, given the ongoing trends of delayed 
childbearing and use of fertility treatments in older mothers. In addition, the role of screening 
on PABC incidence remains unknown, including the sensitivity and participation rates in 
outreach screening programmes among pregnant and lactating women. Should older pregnant 
women be monitored differently compared to younger mothers? 
Although the Swedish quality registers, with information on diagnostic procedures, 
clinicopathologic characteristics and treatments, are a goldmine for an epidemiologist, there 
is a need for collaborations between disciplines to continuously improve the data content and 
how to optimise its use. The new nationally uniform INCA platform is a great improvement 
for data documentation and standardisation, which will make the available information even 
more useable in future research. However, the historic quality register data will remain an 
important source of information for years to come, especially for rare conditions such as 
PABC. Harmonisation of the data structure and variables across different regions would 
therefore be desirable also for the historic quality register data. 
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The combined work included in this thesis shows that with the use of a variety of statistical 
methods, more complex associations and patterns can be assessed for pregnancy-associated 
breast cancer. The condition is rare; hence the data should be used to its full potential. But as 
with any data, the results must be interpreted using subject matter knowledge about the 
underlying biological and clinical processes that generated the information. 
These studies also show that the term pregnancy-associated needs to be discussed and 
perhaps reconsidered. It is clear that some of the short-term time-varying effects of pregnancy 
on BC risk, detection and prognosis are not confined to the pregnancy or the lactation period, 
but may extend up to 2 or 5 years post-delivery. This is often not considered in studies of 
PABC. Studies focussing only on the pregnancy window cannot assess diagnostic delays and 
the possible rebound effect within 2 years of delivery. 
This thesis focuses on breast cancer, which together with malignant melanoma and cervical 
cancer, are the most common cancers in pre-menopausal women in the Nordic countries [58, 
117]. However, patterns of risk and prognosis around pregnancy vary for different 
malignancies. Thus, to improve the understanding of the underlying clinical and biological 
processes, it is of interest to compare different cancer sites with respect to risk, detection, 
tumour characteristics and prognosis. In larger international collaborations, it may also be 
possible to assess rarer cancers in relation to pregnancy.  
In the digital era with increasing amounts of generated data, the knowledge of how to 
compile and extract useful information from data is crucial. We have a responsibility to 
maintain and develop this knowledge among future generations of epidemiologists and 
biostatisticians. Furthermore, the research community has a responsibility to maintain the 
trust of the individuals included in the registers. Research on personal sensitive healthcare 
data must be conducted in such a way that the integrity of individuals is not compromised. 
Lastly, with the goal of improving health, the purpose of medical research is to provide useful 
information for patients, clinicians and healthcare planners. The availability of massive 
datasets underscores the importance for researchers to formulate and prioritise objectives and 
hypotheses prior to starting research projects and analyses. The research community also 
needs to protect the legal foundation to perform register-based research and advocate its 
usefulness and place in science. To date, many studies on PABC have been based on small 
single-institution datasets. In this context, register-based epidemiology can make a difference. 
The studies included in this thesis are some of the largest ever performed on PABC. 
The Nordic countries have a great advantage with their history of population-based registers. 
In an ideal future, clinical data available in these countries should be pooled and analysed in 
consortia. Many of the larger international collaboration studies have been hospital-based 
with suboptimal selection comparison groups. In comparison, joint Nordic collaborations 
would be highly competitive.  
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8 SVENSK SAMMANFATTNING 
Begreppet graviditetsnära bröstcancer (PABC) omfattar vanligtvis tumörer som 
diagnosticerats under graviditet eller inom ett eller två år efter förlossning. Risken att få 
bröstcancer är lägre under graviditet än bland icke-gravida kvinnor i samma ålder, medan den 
är något förhöjd inom två år efter en förlossning. Även om risken att få bröstcancer i samband 
med en graviditet är mycket låg, så tyder resultaten från flera studier på att dessa patienter har 
en sämre överlevnad än andra kvinnor diagnosticerade med bröstcancer i motsvarande ålder. 
Det är därför av stor vikt att identifiera faktorer som kan förklara den förhöjda dödligheten 
bland annat för att öka kunskapen om underliggande mekanismer rörande detektion och 
tumörbiologi. Det är också av intresse att studera tumörer som diagnosticerats upp till tio år 
efter graviditet, eftersom en förhöjd risk även har observerats 5-10 år efter barnafödande. 
Ärftlighet (hereditet) för bröstcancer, dvs. att en nära släkting har haft sjukdomen, utgör en 
etablerad riskfaktor för bröstcancer, särskilt hos unga kvinnor. Kvinnor med hereditet för 
bröstcancer har troligen oftare pre-maligna bröstceller vid ung ålder, och kan därför vara 
särskilt känsliga för graviditetsrelaterade exponeringar, t.ex. förhöjda hormonnivåer. Studie 
III undersökte om riskmönstret för bröstcancer under och upp till tio år efter graviditet är 
annorlunda för kvinnor med hereditet för bröstcancer. En kohort med 3,5 miljoner kvinnor i 
åldrarna 15-44 år identifierades i det svenska flergenerationsregistret och följdes upp för 
bröstcancer i det svenska cancerregistret. Resultaten visade att kvinnor med hereditet för 
bröstcancer hade samma riskmönster nära graviditet som kvinnor utan hereditet, vilket tyder 
på att graviditetsexponeringar inte samspelar med en familjär pre-disposition för bröstcancer. 
Flera studier har visat att tumörer som diagnosticerats nära graviditet har mer aggressiv 
tumörbiologi, t.ex. avancerat TNM-stadium och trippelnegativ tumörtyp, men det är okänt 
om den aggressiva tumörbiologin kan förklara den försämrade prognosen hos kvinnor med 
PABC. Studie II och IV undersökte tumörstorlek, lymfkörtelstatus, grad och tumörmarkörer 
hos patienter diagnosticerade under graviditet och upp till tio år efter förlossning. Studie II 
använde data från det svenska cancerregistret för åren 1963-2002, medan studie IV använde 
data från det svenska kvalitetsregistret för bröstcancer för åren 1992-2009. Resultaten visade 
att tumörer som upptäcktes under graviditet och inom ett år efter förlossningen var mer 
avancerade, höggradiga och hormonreceptor-negativa (trippelnegativa och icke-luminala 
Her2-positiva) jämfört med tumörer hos kvinnor utan barn. Dessa samband var starkast bland 
kvinnor som diagnosticerats under graviditet och inom 6 månader efter förlossning. Mot 
bakgrund av den lägre risken som observerats under graviditet kan detta indikera att 
graviditeten försenar diagnosen, vilket kan leda till mer avancerade tumörer vid upptäckt, 
eller ett undertryckande av hormon-positiva, mindre aggressiva tumörer nära graviditet. 
Studie I och IV undersökte prognosen för kvinnor med PABC i två olika datamaterial; det 
svenska cancerregistret för åren 1963-2002 (studie I) och det svenska kvalitetsregistret för 
bröstcancer för åren 1992-2009 (studie IV). Studie I omfattade 1,110 kvinnor med PABC 
under graviditet och inom två år efter förlossning, medan studie IV omfattade 778 kvinnor 
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med PABC. Studie I bekräftade resultat från tidigare forskning som visat att kvinnor med 
graviditetsnära bröstcancer har en sämre prognos jämfört med icke-graviditetsnära 
bröstcancer. Prognosen var sämst bland kvinnor som diagnosticerats under det första halvåret 
efter graviditet. Skillnaden i prognos mellan grupperna kvarstod upp till åtta år efter diagnos. 
Efter justering för tumörkarakteristik fanns dock inga statistiska skillnader i överlevnad 
mellan grupperna (studie IV). Detta antyder att även om graviditetsnära tumörer oftare är 
avancerade och mer aggressiva, så är prognosen likvärdig med icke-graviditetsnära 
bröstcancer efter justering för tumörkarakteristika. 
Som jämförelse undersöktes även tumörbiologin och prognosen för kvinnor som 
diagnosticerats 2-10 år efter förlossning. En övergående förhöjd risk för bröstcancer 5-10 år 
efter graviditet har tidigare rapporterats, särskilt bland kvinnor med endast ett barn. Kvinnor 
som diagnosticerats 2-5 år efter förlossning hade likvärdiga tumörer som kvinnor utan barn 
med avseende på hormonreceptorstatus och tumörgrad, men de hade oftare spridning till 
lymfkörtlar och icke-luminal Her2-positiv tumörtyp (studie IV). Kvinnor som diagnosticerats 
2-5 år efter förlossning hade också en något försämrad prognos som kvarstod efter justering 
för tumörkarakteristika. Dessa resultat antyder att olika mekanismer för risk, detektion och 
prognos kan föreligga för kvinnor som diagnosticeras 2-5 år efter förlossning jämfört med 
kvinnor med graviditetsnära bröstcancer. 
Slutsatsen från dessa studier är att gravida och ammande kvinnor har ett annat riskmönster för 
bröstcancer samt en annan tumörbiologi och prognos jämfört med andra pre-menopausala 
kvinnor med bröstcancer, samt att effekterna från graviditeten kan kvarstå längre än 2 år efter 
förlossning. 
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9 APPENDIX 1 
The different studies on family history and risk for breast cancer by time-since-pregnancy use 
different parameterisations of the interaction and hence different reference groups. Below I 
try to describe these different comparisons. 
 Wohlfahrt et al [86]: Used the so-called additional birth approach, which compares 
women of a given parity to women without the last birth (i.e. without the additional 
birth). The comparison is made within level of family history. I.e. uniparous women 
with a family history are compared to nulliparous women with a family history; and 
uniparous women without a family history are compared to nulliparous women 
without a family history (Table 9.1). 
 Albrektsen et al [84]: Compared all categories of parity and family history to 
nulliparous women without family history (Table 9.2). The parameterisation will not 
disentangle the interaction effects (contrasts) from the main effects of parity and 
family history, since the comparison group is similar to an overall intercept.  
 Hemminki et al [85]: Compared women within the same level of family history, 
contrasting different intervals of time-since-birth to the average effect in women of 
same parity (Table 9.3). This parameterisation represents a time-since-birth effect 
which is a deviation from the overall mean effect in women of the same parity. It 
separates the main effect of family history from the interaction effect, but it does not 
assess the risk carried by having an additional birth compared to not having the 
additional birth.  
 Hou et al [87]: Compared the effect of family history in different intervals of time-
since-birth and within levels of parity (Table 9.4). This parameterisation does not 
separate the main effect of family history from the interaction effect of family history. 
The different parameterisations imply that the incidence ratios (IRR) are strictly not 
comparable across the studies. Study III (Johansson et al [160]) used the parameterisation as 
in Wohlfahrt et al (Table 9.1). 
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Table 9.1 Parameterisation used in Wohlfahrt et al.  
 Nulliparous Uniparous Biparous 
TSP No fh Fh No fh Fh No fh Fh 
All 1.00 (ref1) 1.00 (ref2) 1.00 (ref3) 1.00 (ref4)   
Pregnant   IRR1 IRR2 IRR3 IRR4 
0-12mo   IRR1 IRR2 IRR3 IRR4 
…   … … … … 
>10 years   IRR1 IRR2 IRR3 IRR4 
Fh=family history. Superscripts represent comparisons to reference group with same superscript. 
 
Table 9.2 Parameterisation used in Albrektsen et al.  
 Nulliparous Uniparous Biparous 
TSP No fh Fh No fh Fh No fh Fh 
All 1.00 (ref1) IRR1     
Pregnant   IRR1 IRR1 IRR1 IRR1 
0-12mo   IRR1 IRR1 IRR1 IRR1 
…   … … … … 
>10 years   IRR1 IRR1 IRR1 IRR1 
Fh=family history. Superscripts represent comparisons to reference group with same superscript. 
 
Table 9.3 Parameterisation used in Hemminki et al.  
 Nulliparous Uniparous Biparous 
TSP No fh Fh No fh Fh No fh Fh 
All N/A N/A 1.00 (ref1) 1.00 (ref2) 1.00 (ref3) 1.00 (ref4) 
Pregnant   IRR1 IRR2 IRR3 IRR4 
0-12mo   IRR1 IRR2 IRR3 IRR4 
…   … … … … 
>10 years   IRR1 IRR2 IRR3 IRR4 
Fh=family history. Superscripts represent comparisons to reference group with same superscript. 
N/A=not available, since the analysis only included parous women. 
 
Table 9.4 Parameterisation used in Hou et al.  
 Nulliparous Uniparous Biparous 
TSP No fh Fh No fh Fh No fh Fh 
All 1.00 (ref1) IRR1     
Pregnant   1.00 (ref2) IRR2 1.00 (ref5) IRR5 
0-12mo   1.00 (ref3) IRR3 1.00 (ref6) IRR6 
…   … … … … 
>10 years   1.00 (ref4) IRR4 1.00 (ref7) IRR7 
Fh=family history. Superscripts represent comparisons to reference group with same superscript. 
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10 APPENDIX 2 
The additional birth approach (study III) 
The same Poisson regression model was used in all analyses (same number of parameters), 
however with different parameterizations. An interaction model for the incidence rate, λ, with 
interaction terms for time-since-pregnancy (tsp) and family history (fh) can be written as 
log(λ)= intercept + β0 tsp0+ β1 tsp1 + … + β8 tsp8 + 
                     + β9 fh1 + β10 fh1 × tsp0 + β11 fh1 × tsp1 + … + β18 fh1 × tsp8 + covariates    (1) 
where tsp0 is an indicator variable for time-since-pregnancy (pregnancy window), tsp1 is an 
indicator for time-since-pregnancy (1st year post-delivery), tsp2 is an indicator for time-since-
pregnancy (2nd year post-delivery), …, tsp8 (>10 years post-delivery). The reference group for 
time-since-pregnancy is nulliparous women who will have all indicator variables set to 0. 
Further, fh1 is an indicator for having a family history (reference group is no family history) 
and the additional covariates are age (spline terms), period (categorized) and education level 
(categorized). 
Parameters β0, β1,…, β8 are interpreted as the effect (log relative rate) of each interval of 
time-since-pregnancy compared to nulliparous among women without a family history. 
Parameter β9 is the log relative rate of family history vs no family history among nulliparous 
women. The interaction parameters β10, β11,…, β18 are interpreted as the excess log relative 
rate carried by having a family history in each time-window during and following pregnancy, 
and above and beyond β9, the effect of family history for nulliparous women. If parameters 
β10, β11,…, β18 are 0 then the effect of time-since-pregnancy is the same in women with and 
without a family history. Hence, the interaction parameters can be used to test for interaction 
between family history and time-since-pregnancy. These parameters are presented in table 2 
(right column), and table 4 (right column). 
To obtain stratum-specific effects of time-since-pregnancy in women stratified with and 
without family history, we parameterized the model as follows: 
log(λ)= intercept + γ9 fh1 + γ00 fh0 × tsp0 + γ01 fh0 × tsp1 + … + γ08 fh0 × tsp8 + 
                     + γ10 fh1 × tsp0 + γ11 fh1 × tsp1 + … + γ18 fh1 × tsp8 + covariates  (2) 
Parameters γ0, γ1,… γ8 are interpreted as the log relative rates of time-since-pregnancy 
compared to nulliparous among women without a family history and γ9 is the effect of family 
history among nulliparous women. Thus, the interpretation is similar to β1, β2,…, β9 in model 
(1). However, parameters γ10, γ11,…, γ18 are no longer the excess log relative rates, but the log 
relative rates of time-since-pregnancy intervals compared to nulliparous among women with 
a family history. These parameters are presented in table 2 (middle columns), and table 4 
(middle columns). 
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There is a direct relationship between the parameters β10, β11,…, β18 and γ10, γ11,…, γ18. Using 
model (1) we can write the log relative rate for the effect of the pregnancy interval vs 
nulliparous among women with family history as: 
log(λtsp0,fh1 / λnulli,fh1)= intercept + β0 tsp0 + β9 fh1 + β10 fh1  × tsp0  - (intercept + β9 fh1) 
   = β0 tsp0 + β10 fh1 × tsp0  = β0 + β10 
Similarly, using model (2) we can write the log relative rate for the effect of the pregnancy 
interval vs nulliparous among women with family history as: 
log(λtsp0,fh1 / λnulli,fh1)= intercept + γ9 fh1  + γ10 fh1 × tsp0 - (intercept + γ9 fh1) 
   = γ10 fh1 × tsp0 = γ10  
Hence, the parameter γ10 is the sum of β0 + β10, that is, the sum of the effect of pregnancy 
among women without a family history (β0) plus the additional effect (interaction effect) of 
having a family history in that interval (β10).  
The interaction term is also a comparison of the log IRRs among women with family history 
compared to without family history, derived as follows: 
log(λtsp0,fh1 / λnulli,fh1)= β0 + β10 
log(λtsp0,fh0 / λnulli,fh0)= intercept + β0 tsp0 - (intercept) 
   = β0 tsp0 = β0 
log([λtsp0,fh1 / λnulli,fh1 ] / [λtsp0,fh0 / λnulli,fh0]) = β0 + β10 - β0= β10 
In table 3, we present parameters from a modified model (2) where the family history 
variable is categorized into 3 levels (without family history, with family history relative’s age 
onset <50 yrs, with family history relative’s age onset >50 yrs), rather than 2 levels 
(with/without family history). 
In table 4, we present parameters from models (1) and (2) but with restrictions to three 
subsets of women; uniparous vs nulliparous, biparous vs uniparous, and triparous vs 
biparous. The reference group of time-since-pregnancy is changed in each subset to 
nulliparous, uniparous and biparous respectively. 
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